@NP	Co-transplantation of olfactory ensheathing glia and mesenchymal stromal cells	1
@NP	Co-transplantation	1
@NP	olfactory ensheathing glia and mesenchymal stromal cells	23
@NP	olfactory ensheathing glia	23
@NP	mesenchymal stromal cells	54
@NP	synergistic effects	94
@NP	spinal cord injury in the rat TAKASHI AMEMORI1	120
@NP	spinal cord injury	120
@NP	the rat TAKASHI AMEMORI1	142
@NP	PAVLA JENDELOVÁ1 ,2	168
@NP	PAVLA JENDELOVÁ1	168
@NP	,2	184
@NP	KATERˇ INA RU ° ŽICˇKOVÁ1	188
@NP	KATERˇ INA	188
@NP	RU ° ŽICˇKOVÁ1	199
@NP	DAVID ARBOLEDA1 & EVA SYKOVÁ1 ,2 1Institute of Experimental Medicine	214
@NP	DAVID ARBOLEDA1 & EVA SYKOVÁ1	214
@NP	,2 1Institute of Experimental Medicine	243
@NP	,2 1Institute	243
@NP	Experimental Medicine	260
@NP	Academy of Sciences of the Czech Republic	283
@NP	Academy	283
@NP	Sciences of the Czech Republic	294
@NP	Sciences	294
@NP	the Czech Republic	306
@NP	Prague , Czech Republic	326
@NP	Prague	326
@NP	Czech Republic	334
@NP	2Department	354
@NP	Neuroscience and Center	369
@NP	Cell Therapy and Tissue Repair	397
@NP	Charles University	429
@NP	2nd Medical Faculty	449
@NP	Prague	470
@NP	Czech Republic Abstract Background	478
@NP	Olfactory ensheathing glia -LRB- OEG -RRB-	519
@NP	Olfactory ensheathing glia	519
@NP	OEG	547
@NP	mesenchymal stromal cells -LRB- MSC -RRB-	556
@NP	mesenchymal stromal cells	556
@NP	MSC	583
@NP	suitable candidates	592
@NP	transplantation therapy of spinal cord injury -LRB- SCI -RRB-	616
@NP	transplantation therapy	616
@NP	spinal cord injury -LRB- SCI -RRB-	643
@NP	spinal cord injury	643
@NP	SCI	663
@NP	Both	669
@NP	functional improvement	685
@NP	SCI	714
@NP	trophic factors and cytokines	731
@NP	this study	765
@NP	the co-transplantation of both types of cells	777
@NP	the co-transplantation	777
@NP	both types of cells	803
@NP	both types	803
@NP	cells	817
@NP	their additive and / or synergistic effects on SCI	846
@NP	their additive	846
@NP	synergistic effects on	869
@NP	synergistic effects	869
@NP	SCI	892
@NP	Methods .	897
@NP	A balloon-induced compression lesion	906
@NP	SCI in rats	963
@NP	SCI	963
@NP	rats	970
@NP	OEG , MSC or both OEG and MSC -LRB- 3 × 105 cells of each cell type -RRB-	976
@NP	OEG , MSC or both OEG and MSC	976
@NP	OEG	976
@NP	MSC	981
@NP	both OEG and MSC	988
@NP	3 × 105 cells of each cell type	1006
@NP	3 ×	1006
@NP	105 cells of each cell type	1010
@NP	105 cells	1010
@NP	each cell type	1023
@NP	intraspinal injection	1057
@NP	1 week	1079
@NP	SCI	1092
@NP	The effect of transplantation	1097
@NP	The effect	1097
@NP	transplantation	1111
@NP	behavioral , electrophysiologic and histologic methods	1146
@NP	Results .	1201
@NP	Hindlimb function	1210
@NP	Basso , Beattie and Bresnahan -LRB- BBB -RRB- and Plantar tests	1246
@NP	Basso , Beattie and Bresnahan -LRB- BBB -RRB-	1246
@NP	Basso , Beattie and Bresnahan	1246
@NP	BBB	1276
@NP	Plantar tests	1285
@NP	Improvement	1300
@NP	all three groups of transplanted rats with different time -- courses	1325
@NP	all three groups	1325
@NP	transplanted rats with different time -- courses	1345
@NP	transplanted rats	1345
@NP	different time -- courses	1368
@NP	different time	1368
@NP	courses	1383
@NP	there	1396
@NP	no signifi cant difference among the groups at the end of the experiment	1406
@NP	no signifi cant difference	1406
@NP	the groups at the end of the experiment	1439
@NP	the groups	1439
@NP	the end of the experiment	1453
@NP	the end	1453
@NP	the experiment	1464
@NP	Motor-evoked potentials after SCI	1480
@NP	Motor-evoked potentials	1480
@NP	SCI	1510
@NP	amplitude	1527
@NP	7 mV	1542
@NP	10 μV	1550
@NP	Linear regression analysis	1557
@NP	a modest recovery	1591
@NP	amplitude following transplantation , but no change in the control rats	1612
@NP	amplitude following transplantation	1612
@NP	amplitude	1612
@NP	transplantation	1632
@NP	no change in the control rats	1653
@NP	no change	1653
@NP	the control rats	1666
@NP	Histologic fi ndings	1684
@NP	the white and gray matter	1717
@NP	transplantation	1773
@NP	SCI	1795
@NP	Conclusions .	1800
@NP	Functional improvement	1813
@NP	transplantation of OEG and/or MSC	1854
@NP	transplantation	1854
@NP	OEG and/or MSC	1873
@NP	OEG	1873
@NP	MSC	1884
@NP	the co-transplantation of OEG and MSC	1893
@NP	the co-transplantation	1893
@NP	OEG and MSC	1919
@NP	synergistic effects	1944
@NP	The poor migration of OEG and MSC	1965
@NP	The poor migration	1965
@NP	OEG and MSC	1987
@NP	their concerted action	2013
@NP	Pre-treatment with a Rho antagonist	2037
@NP	Pre-treatment	2037
@NP	a Rho antagonist	2056
@NP	a combination of intraspinal and intravenous injection of the cells	2077
@NP	a combination	2077
@NP	intraspinal and intravenous injection	2094
@NP	the cells	2135
@NP	benefi cial for SCI therapy	2154
@NP	SCI	2170
@NP	Introduction Cell therapy	2184
@NP	a promising approach	2213
@NP	locomotor function	2247
@NP	spinal cord injury -LRB- SCI -RRB-	2272
@NP	spinal cord injury	2272
@NP	SCI	2292
@NP	Both olfactory ensheathing glia -LRB- OEG -RRB-	2298
@NP	Both olfactory ensheathing glia	2298
@NP	OEG	2331
@NP	mesenchymal stromal cells -LRB- MSC -RRB-	2340
@NP	mesenchymal stromal cells	2340
@NP	MSC	2367
@NP	promising candidates for cell therapy	2410
@NP	promising candidates	2410
@NP	cell therapy	2435
@NP	The implantation of OEG	2449
@NP	The implantation	2449
@NP	OEG	2469
@NP	cavity and scar formation	2494
@NP	astrocytes	2534
@NP	angiogenesis and myelination -LRB- 1,2 -RRB-	2559
@NP	angiogenesis and myelination	2559
@NP	1,2	2589
@NP	OEG	2595
@NP	the levels	2608
@NP	chondroitin sulfate proteoglycan -LRB- CSPG -RRB-	2622
@NP	chondroitin sulfate proteoglycan	2622
@NP	CSPG	2656
@NP	inhibitory effects on growing axons following SCI -LRB- 3,4 -RRB-	2673
@NP	inhibitory effects	2673
@NP	growing axons following SCI -LRB- 3,4 -RRB-	2695
@NP	growing axons	2695
@NP	SCI -LRB- 3,4 -RRB-	2719
@NP	SCI	2719
@NP	3,4	2724
@NP	OEG	2735
@NP	a permissive environment	2755
@NP	axons	2808
@NP	injury	2820
@NP	growth factors	2840
@NP	NGF , BDNF , GDNF and VEGF	2856
@NP	NGF	2856
@NP	BDNF , GDNF and VEGF	2861
@NP	extracellular matrix molecules -LRB- collagen , laminin and fi bronectin -RRB-	2886
@NP	extracellular matrix molecules	2886
@NP	collagen , laminin and fi bronectin	2918
@NP	addition	2957
@NP	adhesion molecules -LRB- 5 -- 7 -RRB-	2969
@NP	adhesion molecules	2969
@NP	5 -- 7	2989
@NP	5	2989
@NP	7	2991
@NP	OEG display phenotypes of both Schwann cells and astrocytes .	2995
@NP	OEG display phenotypes	2995
@NP	both Schwann cells and astrocytes	3021
@NP	They	3056
@NP	Schwann cells	3087
@NP	astrocytes	3106
@NP	astrocytes	3122
@NP	OEG	3153
@NP	oligodendrocytes -LRB- 8 -RRB-	3165
@NP	oligodendrocytes	3165
@NP	8	3183
@NP	These characteristic features of OEG	3187
@NP	These characteristic features	3187
@NP	OEG	3220
@NP	the ingrowth of axons from the peripheral nervous system -LRB- PNS -RRB-	3232
@NP	the ingrowth	3232
@NP	axons from the peripheral nervous system -LRB- PNS -RRB-	3248
@NP	axons	3248
@NP	the peripheral nervous system -LRB- PNS -RRB-	3259
@NP	the peripheral nervous system	3259
@NP	PNS	3290
@NP	the central nervous system -LRB- CNS -RRB-	3298
@NP	the central nervous system	3298
@NP	CNS	3326
@NP	the laminin-rich boundary established following SCI	3338
@NP	the laminin-rich boundary	3338
@NP	SCI	3386
@NP	9	3391
@NP	Au et al. -LRB- 10 -RRB-	3395
@NP	Au et al.	3395
@NP	Au	3395
@NP	et al.	3398
@NP	10	3406
@NP	the production of	3426
@NP	the production	3426
@NP	protein acidic	3453
@NP	cysteine -LRB- SPARC -RRB-	3476
@NP	cysteine	3476
@NP	SPARC	3486
@NP	OEG regulated laminin-1 production	3496
@NP	OEG	3496
@NP	laminin-1 production	3510
@NP	Schwann cells and astrocytes	3543
@NP	the re-entry of regenerating axons into the CNS	3598
@NP	the re-entry	3598
@NP	axons	3627
@NP	the CNS	3638
@NP	MSC	3647
@NP	multipotent progenitor cells	3655
@NP	the case of severe tissue ischemia or damage	3693
@NP	the case	3693
@NP	severe tissue ischemia or damage	3705
@NP	the lesion site , where they can secrete cytokines	3759
@NP	the lesion site	3759
@NP	they	3782
@NP	cytokines	3799
@NP	interleukins	3810
@NP	trophic factors	3828
@NP	an inhibitory infl uence	3859
@NP	scarring and apoptosis	3887
@NP	They	3911
@NP	angiogenesis and neural regeneration -LRB- 11 -RRB-	3927
@NP	angiogenesis and neural regeneration	3927
@NP	11	3965
@NP	the bone marrow -LRB- BM -RRB-	3985
@NP	the bone marrow	3985
@NP	BM	4002
@NP	culture	4033
@NP	MSC	4042
@NP	the damaged site	4066
@NP	direct or systemic application	4086
@NP	Their easy accessibility and rapid expansion in culture	4686
@NP	Their easy accessibility and rapid expansion	4686
@NP	culture	4734
@NP	attractive characteristics from a therapeutic point of view	4746
@NP	attractive characteristics	4746
@NP	a therapeutic point of view	4778
@NP	a therapeutic point	4778
@NP	view	4801
@NP	The co-transplantation of OEG and MSC	4807
@NP	The co-transplantation	4807
@NP	OEG and MSC	4833
@NP	benefi cial for SCI treatment	4852
@NP	SCI	4868
@NP	a combinatory approach	4890
@NP	OEG	4914
@NP	regeneration	4933
@NP	SCI	4956
@NP	guiding strands and molecules of the extracellular matrix for axonal ingrowth	4973
@NP	guiding strands and molecules	4973
@NP	the extracellular matrix for axonal ingrowth	5006
@NP	the extracellular matrix	5006
@NP	axonal ingrowth	5035
@NP	other cell types such as MSC	5058
@NP	other cell types	5058
@NP	MSC	5083
@NP	functional outcome	5099
@NP	trophic factors and cytokines	5131
@NP	addition	5165
@NP	OEG as well as MSC	5175
@NP	OEG	5175
@NP	MSC	5190
@NP	autologous transplantation protocols	5209
@NP	no additional immunosuppression	5261
@NP	this study	5316
@NP	the effect	5328
@NP	the transplantation of OEG , MSC	5342
@NP	the transplantation	5342
@NP	OEG , MSC	5365
@NP	the co-transplantation	5378
@NP	both OEG and MSC	5404
@NP	OEG	5409
@NP	MSC	5417
@NP	behavioral , electrophysiologic and histologic outcomes	5424
@NP	SCI	5485
@NP	Methods Adult male Wistar rats	5503
@NP	Methods	5503
@NP	Adult male Wistar rats	5511
@NP	270	5543
@NP	300 g	5547
@NP	our experiments	5566
@NP	The lesioned animals	5583
@NP	four groups	5622
@NP	The fi rst group	5635
@NP	both OEG and MSC -LRB- n = 21 -RRB-	5661
@NP	both OEG and MSC	5661
@NP	OEG	5666
@NP	MSC	5674
@NP	n	5679
@NP	21	5683
@NP	The second and third groups	5688
@NP	only OEG -LRB- n = 22 -RRB- or MSC -LRB- n = 23 -RRB-	5739
@NP	only OEG	5739
@NP	n	5749
@NP	22	5753
@NP	MSC	5760
@NP	n	5765
@NP	23	5769
@NP	The fourth group	5788
@NP	saline	5823
@NP	a control -LRB- n = 23 -RRB-	5833
@NP	a control	5833
@NP	n	5844
@NP	23	5848
@NP	All experiments	5853
@NP	accordance with the European Communities	5887
@NP	accordance	5887
@NP	the European Communities	5903
@NP	Council Directive	5928
@NP	24th of November 1986	5949
@NP	24th	5949
@NP	November 1986	5957
@NP	86/609/EEC	5972
@NP	the use of animals in research	5994
@NP	the use	5994
@NP	animals in research	6005
@NP	animals	6005
@NP	research	6016
@NP	the Ethics Committee of the Institute of Experimental Medicine ASCR , Prague ,	6047
@NP	the Ethics Committee	6047
@NP	the Institute of Experimental Medicine ASCR , Prague ,	6071
@NP	the Institute	6071
@NP	Experimental Medicine ASCR , Prague ,	6088
@NP	Experimental Medicine ASCR	6088
@NP	Prague	6116
@NP	Czech Republic	6124
@NP	SCI Balloon compression	6140
@NP	an SCI	6183
@NP	A small opening of the thoracic vertebra 10 -LRB- T10 -RRB-	6191
@NP	A small opening	6191
@NP	the thoracic vertebra 10 -LRB- T10 -RRB-	6210
@NP	the thoracic vertebra 10	6210
@NP	T10	6236
@NP	A 2-french Fogarty catheter	6256
@NP	T8	6303
@NP	the balloon	6311
@NP	15 μL saline for 5 min at T8 -LRB- 19,21 -RRB-	6342
@NP	15 μL saline	6342
@NP	5 min at T8 -LRB- 19,21 -RRB-	6359
@NP	5 min	6359
@NP	T8 -LRB- 19,21 -RRB-	6368
@NP	T8	6368
@NP	19,21	6372
@NP	the surgical procedure	6387
@NP	the body temperature of the animal	6411
@NP	the body temperature	6411
@NP	the animal	6435
@NP	37 °C with a heating pad	6464
@NP	37 °C	6464
@NP	a heating pad	6474
@NP	3 % isofl urane in air	6493
@NP	3 % isofl urane	6493
@NP	air	6511
@NP	a fl ow rate of 0.3 L/min	6535
@NP	a fl ow rate	6535
@NP	0.3 L/min	6551
@NP	edema development	6572
@NP	a result of low levels of anesthesia -LRB- 22 -RRB-	6593
@NP	a result	6593
@NP	low levels of anesthesia -LRB- 22 -RRB-	6605
@NP	low levels	6605
@NP	anesthesia -LRB- 22 -RRB-	6619
@NP	anesthesia	6619
@NP	22	6631
@NP	the lesioning procedure	6646
@NP	the rats	6671
@NP	feeding and urination	6697
@NP	they	6725
@NP	these functions	6769
@NP	their own	6788
@NP	The animals	6799
@NP	gentamicin sulfate -LRB- 5 mg/kg -RRB- for 3 days	6820
@NP	gentamicin sulfate -LRB- 5 mg/kg -RRB-	6820
@NP	gentamicin sulfate	6820
@NP	5 mg/kg	6840
@NP	3 days	6853
@NP	post-operative infections	6871
@NP	OEG preparation and identifi cation OEG	6898
@NP	OEG preparation	6898
@NP	identifi cation OEG	6918
@NP	4-week-old Wistar rats	6957
@NP	The olfactory mucosa	6981
@NP	both sides of the nasal septum	7019
@NP	both sides	7019
@NP	the nasal septum	7033
@NP	incubation	7057
@NP	Dispase II -LRB- Roche , Mannheim , Germany -RRB- , the lamina propria	7071
@NP	Dispase II -LRB- Roche , Mannheim , Germany -RRB-	7071
@NP	Dispase II	7071
@NP	Roche	7083
@NP	Mannheim	7090
@NP	Germany	7100
@NP	the lamina propria	7110
@NP	the epithelium	7161
@NP	collagenase type	7197
@NP	I -LRB- Sigma , St.	7214
@NP	I	7214
@NP	Sigma	7217
@NP	St.	7224
@NP	Louis , MO , USA -RRB- -LRB- 23 -RRB- .	7228
@NP	Louis , MO , USA -RRB- -LRB- 23 -RRB-	7228
@NP	Louis , MO , USA -RRB-	7228
@NP	Louis	7228
@NP	MO	7235
@NP	USA	7239
@NP	23	7245
@NP	a 24-h incubation in Dulbecco 's modifi	7256
@NP	a 24-h incubation	7256
@NP	Dulbecco 's modifi	7277
@NP	Dulbecco 's	7277
@NP	Eagle medium -LRB- DMEM -RRB- / F12 with 10 % fetal bovine serum	7298
@NP	Eagle medium -LRB- DMEM -RRB-	7298
@NP	Eagle medium	7298
@NP	DMEM	7312
@NP	F12 with 10 % fetal bovine serum	7318
@NP	F12	7318
@NP	10 % fetal bovine serum	7327
@NP	the cells	7351
@NP	5 × 10 -- 5 M ; Sigma	7411
@NP	5	7411
@NP	× 10 -- 5 M ; Sigma	7413
@NP	× 10	7413
@NP	5 M ; Sigma	7418
@NP	5 M	7418
@NP	Sigma	7423
@NP	cells , such as fi broblasts ,	7460
@NP	cells	7460
@NP	fi broblasts	7475
@NP	bovine pituitary extract -LRB- 100 μg/mL ; Sigma -RRB- -LRB- 24 -RRB-	7507
@NP	bovine pituitary extract -LRB- 100 μg/mL ; Sigma -RRB-	7507
@NP	bovine pituitary extract	7507
@NP	100 μg/mL ; Sigma	7533
@NP	100 μg/mL	7533
@NP	Sigma	7544
@NP	24	7552
@NP	the purity of OEG cultures , cultured cells on glass slides	7567
@NP	the purity	7567
@NP	OEG cultures , cultured cells on glass slides	7581
@NP	OEG cultures	7581
@NP	cells	7604
@NP	glass slides	7613
@NP	4 % paraformaldehyde , permeabilized in 0.1 % Triton X-100	7641
@NP	4 % paraformaldehyde	7641
@NP	permeabilized in 0.1 % Triton X-100	7662
@NP	0.1 %	7679
@NP	serum	7709
@NP	primary antibodies	7735
@NP	overnight at 4 °C	7754
@NP	overnight	7754
@NP	4 °C	7767
@NP	Two antibodies	7772
@NP	OEG : mouse anti-p75	7809
@NP	OEG	7809
@NP	mouse anti-p75	7814
@NP	low-affi nity nerve	7830
@NP	growth factor receptor -LRB- 1:100 ; Chemicon , Temecula , CA , USA -RRB-	7850
@NP	growth factor receptor	7850
@NP	1:100 ; Chemicon , Temecula , CA , USA	7874
@NP	1:100	7874
@NP	Chemicon , Temecula , CA , USA	7881
@NP	rabbit anti-S100 -LRB- 1:200 ; Sigma -RRB-	7915
@NP	rabbit anti-S100	7915
@NP	1:200 ; Sigma	7933
@NP	1:200	7933
@NP	Sigma	7940
@NP	Alexa Fluor 488-conjugated goat anti-mouse IgG	7948
@NP	Alexa Fluor	7948
@NP	488-conjugated goat anti-mouse IgG	7960
@NP	Alexa Fluor	7999
@NP	594-conjugated goat anti-rabbit IgG secondary antibodies -LRB- Sigma -RRB-	8011
@NP	594-conjugated goat anti-rabbit IgG secondary antibodies	8011
@NP	Sigma	8069
@NP	the two primary antibodies	8101
@NP	cells	8137
@NP	a fl	8160
@NP	uorescent microscope -LRB- Zeiss Axioskop , Göttingen , Germany -RRB-	8165
@NP	uorescent microscope	8165
@NP	Zeiss Axioskop	8187
@NP	Göttingen	8203
@NP	Germany	8214
@NP	More than 80 % of cultured cells	8224
@NP	More than 80 %	8224
@NP	cells	8250
@NP	MSC preparation BM	8280
@NP	the tibia and femur of 4-week-old Wistar rats	8318
@NP	the tibia and femur	8318
@NP	4-week-old Wistar rats	8341
@NP	fl ushing with DMEM	8367
@NP	fl	8367
@NP	DMEM	8382
@NP	BM cells	8388
@NP	DMEM medium	8441
@NP	10 % fetal bovine serum	8471
@NP	100 U/mL penicillin	8495
@NP	0.1 mg/mL streptomycin -LRB- Gibco -RRB-	8519
@NP	0.1 mg/mL streptomycin	8519
@NP	Gibco	8543
@NP	MSC	8551
@NP	their adherence	8577
@NP	plastic	8596
@NP	a 24-h incubation	8611
@NP	non-adherent cells , including hematopoietic stem cells ,	8630
@NP	non-adherent cells	8630
@NP	hematopoietic stem cells	8660
@NP	the medium -LRB- 19,25 -RRB-	8712
@NP	the medium	8712
@NP	19,25	8724
@NP	MSC	8732
@NP	transplantation	8750
@NP	6	8772
@NP	10 passages	8774
@NP	Transplantation The animals	8787
@NP	Transplantation	8787
@NP	The animals	8803
@NP	transplanted 1 week	8820
@NP	SCI	8846
@NP	transplantation , OEG	8863
@NP	transplantation	8863
@NP	OEG	8880
@NP	the fl uorescent	8902
@NP	10 μM carboxy-fl uorescein	8923
@NP	diacetate succinimidyl ester	8950
@NP	CFDA-SE ; green fl uorescence ; Molecular Probes , Eugene , OR , USA	8980
@NP	CFDA-SE	8980
@NP	green fl uorescence ; Molecular Probes , Eugene , OR , USA	8989
@NP	green fl uorescence	8989
@NP	Molecular Probes , Eugene , OR , USA	9010
@NP	Molecular Probes	9010
@NP	Eugene	9028
@NP	OR	9036
@NP	USA	9040
@NP	MSC	9052
@NP	20 μM carboxy SNARF-1	9074
@NP	red fl uorescence ; Molecular Probes	9097
@NP	red fl uorescence	9097
@NP	Molecular Probes	9116
@NP	CFDA-SE	9137
@NP	subsequent identifi cation of transplanted cells	9156
@NP	subsequent identifi cation	9156
@NP	transplanted cells	9186
@NP	the manufacturer 's instructions	9242
@NP	the manufacturer 's	9242
@NP	the concentrations of the tracers	9279
@NP	the concentrations	9279
@NP	the tracers	9301
@NP	the results of Imaizumi et al. -LRB- 26 -RRB- and Li et al. -LRB- 27 -RRB-	9327
@NP	the results	9327
@NP	Imaizumi et al. -LRB- 26 -RRB- and Li et al. -LRB- 27 -RRB-	9342
@NP	Imaizumi et al. -LRB- 26 -RRB-	9342
@NP	Imaizumi	9342
@NP	et al. -LRB- 26 -RRB-	9351
@NP	et al.	9351
@NP	26	9359
@NP	Li et al. -LRB- 27 -RRB-	9367
@NP	Li	9367
@NP	et al. -LRB- 27 -RRB-	9370
@NP	et al.	9370
@NP	27	9378
@NP	The animals	9383
@NP	a stereotaxic apparatus	9411
@NP	the spinal process	9446
@NP	the injured site of the spinal cord with a ratspecifi c vertebra holder	9482
@NP	the injured site	9482
@NP	the spinal cord with a ratspecifi c vertebra holder	9502
@NP	the spinal cord	9502
@NP	a ratspecifi c vertebra holder	9523
@NP	Cunningham spinal adaptor ; Stoelting Co.	9555
@NP	Cunningham spinal adaptor	9555
@NP	Stoelting Co.	9582
@NP	Wood Dale , IL , USA	9597
@NP	Wood Dale	9597
@NP	IL	9608
@NP	USA	9612
@NP	The spinal cord	9618
@NP	T8	9649
@NP	The glass pipette	10132
@NP	place	10162
@NP	each injection for a further minute	10174
@NP	each injection	10174
@NP	a further minute	10193
@NP	leakage of the cell suspension	10221
@NP	leakage	10221
@NP	the cell suspension	10232
@NP	The control group	10253
@NP	three injections of saline -LRB- 1 μL/injection -RRB-	10280
@NP	three injections	10280
@NP	saline	10300
@NP	1 μL/injection	10308
@NP	the proximal , central and distal parts of the lesioned spinal cord	10335
@NP	the proximal , central and distal parts	10335
@NP	the lesioned spinal cord	10377
@NP	Cyclosporine -LRB- 10 mg/kg -RRB- and ampicillin -LRB- 50 -- 100 mg / kg -RRB-	10403
@NP	Cyclosporine -LRB- 10 mg/kg -RRB-	10403
@NP	Cyclosporine	10403
@NP	10 mg/kg	10417
@NP	ampicillin -LRB- 50 -- 100 mg / kg -RRB-	10431
@NP	ampicillin	10431
@NP	50 -- 100 mg / kg	10443
@NP	50	10443
@NP	100 mg	10446
@NP	kg	10454
@NP	1 day	10494
@NP	transplantation	10507
@NP	the experiment	10538
@NP	2 months	10558
@NP	OEG and MSC	10569
@NP	green fl uorescent protein transgenic rats	10586
@NP	easily distinguishable and stable tracking of transplanted cells	10644
@NP	easily distinguishable and stable tracking	10644
@NP	transplanted cells	10690
@NP	OEG and MSC expressing	10710
@NP	green fl uorescent protein -LRB- GFP -RRB- isolated from GFP + rats	10742
@NP	green fl uorescent protein -LRB- GFP -RRB-	10742
@NP	green fl uorescent protein	10742
@NP	GFP	10770
@NP	GFP + rats	10789
@NP	GFP	10789
@NP	rats	10794
@NP	2-month survival experiments	10812
@NP	Transgenic Sprague	10842
@NP	Dawley rats	10861
@NP	SD-Tg -LRB- CAG-EGFP -RRB- CZ-004Osb	10874
@NP	SD-Tg -LRB- CAG-EGFP -RRB-	10874
@NP	SD-Tg	10874
@NP	CAG-EGFP	10880
@NP	CZ-004Osb	10889
@NP	Dr Masaru Okabe -LRB- Osaka University , Osaka , Japan -RRB- -LRB- 28 -RRB-	10924
@NP	Dr Masaru Okabe -LRB- Osaka University , Osaka , Japan -RRB-	10924
@NP	Dr Masaru Okabe	10924
@NP	Osaka University	10941
@NP	Osaka	10959
@NP	Japan	10966
@NP	28	10974
@NP	the laboratory	10987
@NP	Dr Martin Marsala -LRB- University of California , San Diego , CA , USA -RRB-	11005
@NP	Dr Martin Marsala	11005
@NP	University of California	11024
@NP	University	11024
@NP	California	11038
@NP	San Diego , CA , USA	11050
@NP	San Diego	11050
@NP	CA , USA	11061
@NP	our institute	11095
@NP	our animal facility	11121
@NP	Functional analysis	11142
@NP	Hindlimb locomotor activity	11162
@NP	SCI	11196
@NP	the Basso , Beattie and Bresnahan -LRB- BBB -RRB- test -LRB- 29 -RRB-	11216
@NP	the Basso , Beattie and Bresnahan -LRB- BBB -RRB- test	11216
@NP	Basso , Beattie and Bresnahan -LRB- BBB -RRB-	11220
@NP	Basso , Beattie and Bresnahan	11220
@NP	BBB	11250
@NP	29	11261
@NP	OEG/MSC , n = 14 ; OEG , n = 15 ; MSC , n = 16 ; control , n = 12	11266
@NP	OEG/MSC	11266
@NP	n = 14 ; OEG , n = 15 ; MSC , n = 16 ; control , n = 12	11275
@NP	n = 14	11275
@NP	n	11275
@NP	14	11279
@NP	OEG , n = 15	11283
@NP	OEG	11283
@NP	n = 15	11288
@NP	n	11288
@NP	15	11292
@NP	MSC , n = 16	11296
@NP	MSC	11296
@NP	n = 16	11301
@NP	n	11301
@NP	16	11305
@NP	control , n = 12	11309
@NP	control	11309
@NP	n = 12	11318
@NP	n	11318
@NP	12	11322
@NP	The rats	11327
@NP	a fl oor within a circular enclosure	11351
@NP	a fl oor	11351
@NP	a circular enclosure	11367
@NP	Basso	11404
@NP	et al. -LRB- 29 -RRB-	11410
@NP	et al.	11410
@NP	29	11418
@NP	Their hindlimb joint movement	11423
@NP	paw placement , weight support , forelimb -- hindlimb co-ordination , etc.	11454
@NP	paw placement	11454
@NP	weight support , forelimb -- hindlimb co-ordination	11469
@NP	weight support , forelimb	11469
@NP	weight support	11469
@NP	hindlimb co-ordination	11494
@NP	a 0 -- 21-point scale	11545
@NP	a 0	11545
@NP	21-point scale	11549
@NP	Hindpaw withdrawal latency to a noxious thermal stimuli	11565
@NP	Hindpaw withdrawal latency	11565
@NP	a noxious thermal stimuli	11595
@NP	a Plantar test apparatus -LRB- Ugo Basile , Comerio , Italy -RRB-	11639
@NP	a Plantar test apparatus	11639
@NP	Ugo Basile	11665
@NP	Comerio	11677
@NP	Italy	11686
@NP	OEG/MSC , n = 10 ; OEG , n = 10 ; MSC , n = 10 ; control , n = 10	11694
@NP	OEG/MSC	11694
@NP	n = 10 ; OEG , n = 10 ; MSC , n = 10 ; control , n = 10	11703
@NP	n = 10	11703
@NP	n	11703
@NP	10	11707
@NP	OEG , n = 10	11711
@NP	OEG	11711
@NP	n = 10	11716
@NP	n	11716
@NP	10	11720
@NP	MSC , n = 10	11724
@NP	MSC	11724
@NP	n = 10	11729
@NP	n	11729
@NP	10	11733
@NP	control , n = 10	11737
@NP	control	11737
@NP	n = 10	11746
@NP	n	11746
@NP	10	11750
@NP	The animals	11755
@NP	a clear plastic chamber	11782
@NP	10 min	11825
@NP	quiescent	11847
@NP	The hindpaw	11858
@NP	a heat stimulus	11879
@NP	a glass plate	11903
@NP	The withdrawal latencies	11918
@NP	three times	11957
@NP	each hindpaw at 5-min intervals	11973
@NP	each hindpaw	11973
@NP	5-min intervals	11989
@NP	The average of three values	12006
@NP	The average	12006
@NP	three values	12021
@NP	statistical evaluation	12047
@NP	Motor-evoked potentials Rats	12071
@NP	ketamine -LRB- 100 mg/kg -RRB-	12123
@NP	ketamine	12123
@NP	100 mg/kg	12133
@NP	One pair of needle electrodes	12145
@NP	One pair	12145
@NP	needle electrodes	12157
@NP	the skull for cortical stimulation	12206
@NP	the skull	12206
@NP	cortical stimulation	12220
@NP	another pair in the gastrocnemius muscle for recording	12245
@NP	another pair	12245
@NP	the gastrocnemius muscle for recording	12261
@NP	the gastrocnemius muscle	12261
@NP	recording	12290
@NP	The signals	12301
@NP	fi ltered -LRB- 1 -- 5000 Hz -RRB-	12318
@NP	fi	12318
@NP	1 -- 5000 Hz	12329
@NP	1	12329
@NP	5000 Hz	12331
@NP	a Medelec Synergy T-EP EMG/EP Monitoring System	12356
@NP	Oxford Instruments Medical Inc.	12405
@NP	Surrey	12438
@NP	UK	12446
@NP	Motor-evoked potentials -LRB- MEP -RRB-	12451
@NP	Motor-evoked potentials	12451
@NP	MEP	12476
@NP	once a week	12495
@NP	transcranial stimulation	12510
@NP	a single square-pulse electrical stimulus of 0.1 ms in duration	12536
@NP	a single square-pulse electrical stimulus	12536
@NP	0.1 ms in duration	12581
@NP	0.1 ms	12581
@NP	duration	12591
@NP	the amplitude	12612
@NP	latency	12627
@NP	onset and duration	12638
@NP	the response	12660
@NP	OEG/MSC , n = 9 ; OEG , n = 10 ; MSC , n = 11 ; control , n = 7	12674
@NP	OEG/MSC	12674
@NP	n = 9 ; OEG , n = 10 ; MSC , n = 11 ; control , n = 7	12683
@NP	n = 9	12683
@NP	n	12683
@NP	9	12687
@NP	OEG , n = 10	12690
@NP	OEG	12690
@NP	n = 10	12695
@NP	n	12695
@NP	10	12699
@NP	MSC , n = 11	12703
@NP	MSC	12703
@NP	n = 11	12708
@NP	n	12708
@NP	11	12712
@NP	control , n = 7	12716
@NP	control	12716
@NP	n = 7	12725
@NP	n	12725
@NP	7	12729
@NP	the number of transplanted GFP cells	12762
@NP	the number	12762
@NP	transplanted GFP cells	12776
@NP	the possible neural differentiation of the transplanted cells	12811
@NP	the possible neural differentiation	12811
@NP	the transplanted cells	12850
@NP	longitudinal cryostat sections -LRB- 40-μm thickness -RRB- of the spinal cord	12874
@NP	longitudinal cryostat sections -LRB- 40-μm thickness -RRB-	12874
@NP	longitudinal cryostat sections	12874
@NP	40-μm thickness	12906
@NP	the spinal cord	12926
@NP	4 % paraformaldehyde fi xation	12958
@NP	4 %	12958
@NP	paraformaldehyde fi xation	12961
@NP	Every sixth section	12989
@NP	imaging	13024
@NP	a fl uorescent microscope	13038
@NP	The surviving cells	13065
@NP	each section	13101
@NP	the total number of cells	13119
@NP	the total number	13119
@NP	cells	13139
@NP	the volume of the section in which the cells were found	13172
@NP	the volume	13172
@NP	the section in which the cells were found	13186
@NP	the section	13186
@NP	the cells	13207
@NP	The percentage of surviving transplanted cells	13229
@NP	The percentage	13229
@NP	transplanted cells	13257
@NP	the estimated total number of surviving cells	13303
@NP	the estimated total number	13303
@NP	surviving cells	13333
@NP	the total number of transplanted cells -LRB- 3 × 105 cells/rat -RRB-	13352
@NP	the total number	13352
@NP	transplanted cells -LRB- 3 × 105 cells/rat -RRB-	13372
@NP	transplanted cells	13372
@NP	3 × 105 cells/rat	13392
@NP	3 ×	13392
@NP	105 cells/rat	13396
@NP	immunohistochemistry	13416
@NP	the sections	13438
@NP	1 % bovine serum albumin	13469
@NP	antibodies	13514
@NP	neural markers	13533
@NP	1:2500 ; Chemicon	13562
@NP	1:2500	13562
@NP	Chemicon	13570
@NP	1:400 ; Sigma	13602
@NP	1:400	13602
@NP	Sigma	13609
@NP	4 °C	13629
@NP	incubation	13646
@NP	the Alexa Fluor 594-conjugated secondary antibody	13662
@NP	axon tracts	13741
@NP	SCI	13759
@NP	the corticospinal tract	13764
@NP	one of the major descending tracts in the spinal cord	13789
@NP	one	13789
@NP	the major descending tracts in the spinal cord	13796
@NP	the major descending tracts	13796
@NP	the spinal cord	13827
@NP	Two weeks	13871
@NP	termination of the experiment	13888
@NP	termination	13888
@NP	the experiment	13903
@NP	1 μL	13919
@NP	a 10 % biotinylated dextran amine -LRB- BDA ; 10 000 MW ; Molecular Probes -RRB-	13927
@NP	a 10 %	13927
@NP	dextran amine -LRB- BDA ; 10 000 MW ; Molecular Probes -RRB-	13946
@NP	dextran amine	13946
@NP	BDA	13961
@NP	10 000 MW ; Molecular Probes	13966
@NP	10 000 MW	13966
@NP	Molecular Probes	13977
@NP	the sensorimotor cortex	14025
@NP	a depth of 1.5 mm	14052
@NP	a depth	14052
@NP	1.5 mm	14063
@NP	the surface with a glass micropipette	14075
@NP	the surface	14075
@NP	a glass micropipette	14092
@NP	BDA-injected animals	14114
@NP	ketamine -LRB- 100 mg/kg -RRB- and xylazine -LRB- 20 mg/kg -RRB-	14166
@NP	ketamine	14166
@NP	100 mg/kg	14176
@NP	xylazine	14191
@NP	20 mg/kg	14201
@NP	their chests	14212
@NP	transcardial perfusion	14236
@NP	phosphate buffer followed by 4 % paraformaldehyde solution in phosphate buffer	14274
@NP	phosphate buffer	14274
@NP	4 % paraformaldehyde solution in phosphate buffer	14303
@NP	4 % paraformaldehyde solution	14303
@NP	phosphate buffer	14335
@NP	The spinal column	14353
@NP	paraformaldehyde solution overnight	14395
@NP	paraformaldehyde solution	14395
@NP	The spinal cord	14432
@NP	the spinal cord channel and post-fi xed in the same solution for at least 1 week	14480
@NP	the spinal cord channel	14480
@NP	post-fi xed in the same solution for at least 1 week	14508
@NP	post-fi	14508
@NP	the same solution for at least 1	14523
@NP	the same solution	14523
@NP	at least 1	14545
@NP	week	14556
@NP	An approximately 5-cm long segment from the same area of each spinal cord	14562
@NP	An approximately 5-cm long segment	14562
@NP	the same area of each spinal cord	14602
@NP	the same area	14602
@NP	each spinal cord	14619
@NP	14-μm thick sagittal frozen sections	14655
@NP	the BDA-injected corticospinal tract axons	14715
@NP	cryostat sections	14759
@NP	avidin horseradish peroxidase	14797
@NP	diaminobenzidine	14831
@NP	DAB	14849
@NP	the instructions in the BDA neuronal tracer kit -LRB- Molecular Probes -RRB-	14865
@NP	the instructions	14865
@NP	the BDA neuronal tracer kit -LRB- Molecular Probes -RRB-	14885
@NP	the BDA neuronal tracer kit	14885
@NP	Molecular Probes	14914
@NP	Some sections	14933
@NP	hematoxylin-eosin	14965
@NP	Spinal compression	14984
@NP	the formation of cavities within the spinal cord tissue	15014
@NP	the formation	15014
@NP	cavities within the spinal cord tissue	15031
@NP	cavities	15031
@NP	the spinal cord tissue	15047
@NP	degeneration of the spinal cord	15082
@NP	degeneration	15082
@NP	the spinal cord	15098
@NP	The volume of the spared white and gray matter	15115
@NP	The volume	15115
@NP	the spared white and gray matter	15129
@NP	the end of the experiment	15178
@NP	the end	15178
@NP	the experiment	15189
@NP	perfusion with 4 % paraformaldehyde	15211
@NP	perfusion	15211
@NP	4 % paraformaldehyde	15226
@NP	a 2-cm long segment of the spinal cord	15247
@NP	a 2-cm long segment	15247
@NP	the spinal cord	15270
@NP	1-cm cranial and 1-cm caudal	15308
@NP	the injury epicenter	15340
@NP	Serial cross-sections -LRB- 5 μm thick -RRB-	15362
@NP	Serial cross-sections	15362
@NP	5 μm	15385
@NP	paraffi n embedding	15413
@NP	paraffi n	15413
@NP	Luxol-fast blue and Cresyl violet	15450
@NP	the white and gray matter	15499
@NP	volumetric measurements	15530
@NP	six sections	15555
@NP	1-mm intervals along the cranio-caudal axis	15585
@NP	1-mm intervals	15585
@NP	the cranio-caudal axis	15606
@NP	whole images of the spinal cord	15634
@NP	whole images	15634
@NP	the spinal cord	15650
@NP	an Axioskop 2 plus microscope -LRB- Zeiss -RRB-	15682
@NP	an Axioskop 2	15682
@NP	microscope -LRB- Zeiss -RRB-	15701
@NP	microscope	15701
@NP	Zeiss	15713
@NP	ImageJ software	15736
@NP	Wayne Rasband , National Institutes of Health , Bethesda , MD , USA	15753
@NP	Wayne Rasband	15753
@NP	National Institutes of Health , Bethesda , MD	15768
@NP	National Institutes	15768
@NP	Health , Bethesda , MD	15791
@NP	USA	15813
@NP	19	15819
@NP	Statistical analysis The data	15824
@NP	Statistical analysis	15824
@NP	The data	15845
@NP	mean ± SEM	15871
@NP	A one-way analysis	15883
@NP	variance	15905
@NP	ANOVA	15915
@NP	Tukey 's posthoc test	15934
@NP	Tukey 's	15934
@NP	differences between groups	15976
@NP	differences	15976
@NP	groups	15996
@NP	Regression analyzes	16004
@NP	MEP	16041
@NP	A P-value < 0.05	16046
@NP	A P-value <	16046
@NP	0.05	16058
@NP	statistically signifi cant	16078
@NP	Results Figure 1 .	16107
@NP	Results	16107
@NP	Figure 1	16115
@NP	-LRB- A -RRB- BBB open-fi eld locomotor scores .	16125
@NP	-LRB- A -RRB-	16125
@NP	BBB open-fi eld locomotor scores	16129
@NP	BBB	16129
@NP	open-fi eld locomotor scores	16133
@NP	Hindlimb gait	16163
@NP	fi rst	16181
@NP	1 week after SCI , i.e. before transplantation -LRB- Tx -RRB-	16197
@NP	1 week after SCI , i.e.	16197
@NP	1 week	16197
@NP	SCI	16210
@NP	transplantation -LRB- Tx -RRB-	16227
@NP	transplantation	16227
@NP	Tx	16244
@NP	weekly	16263
@NP	rats	16295
@NP	any signifi	16315
@NP	cant differences between one other	16327
@NP	cant differences	16327
@NP	one other	16352
@NP	a signifi cant difference	16367
@NP	7 weeks	16405
@NP	SCI	16419
@NP	all of the transplanted groups and the control group -LRB- ∗ P < 0.05 -RRB-	16431
@NP	all	16431
@NP	the transplanted groups and the control group -LRB- ∗ P < 0.05 -RRB-	16438
@NP	the transplanted groups	16438
@NP	the control group -LRB- ∗ P < 0.05 -RRB-	16466
@NP	the control group	16466
@NP	∗ P < 0.05	16485
@NP	∗ P	16485
@NP	< 0.05	16488
@NP	<	16488
@NP	0.05	16490
@NP	-LRB- B -RRB-	16497
@NP	The latency	16501
@NP	seconds	16517
@NP	the hindlimb in response	16538
@NP	the hindlimb	16538
@NP	response	16554
@NP	a heat stimulus	16566
@NP	the Plantar test	16598
@NP	rats	16629
@NP	their response	16643
@NP	the thermal stimulus	16661
@NP	a signifi cant difference compared to the control group	16683
@NP	a signifi cant difference	16683
@NP	the control group	16721
@NP	6 weeks after SCI in the OEG - and MSC-transplanted groups and from 7 weeks	16754
@NP	6 weeks	16754
@NP	SCI in the OEG - and MSC-transplanted groups	16768
@NP	SCI	16768
@NP	the OEG	16775
@NP	MSC-transplanted groups	16788
@NP	7 weeks	16821
@NP	SCI in the OEG/MSC-transplanted group -LRB- ∗ P < 0.05 -RRB-	16835
@NP	SCI	16835
@NP	the OEG/MSC-transplanted group -LRB- ∗ P < 0.05 -RRB-	16842
@NP	the OEG/MSC-transplanted group	16842
@NP	∗ P < 0.05	16874
@NP	∗ P	16874
@NP	< 0.05	16877
@NP	<	16877
@NP	0.05	16879
@NP	Tx	16886
@NP	the day of transplantation	16895
@NP	the day	16895
@NP	transplantation	16906
@NP	Figure 2 .	16924
@NP	Figure	16924
@NP	2	16931
@NP	Representative MEP	16934
@NP	transplanted and control rats 6 weeks after SCI -LRB- A -RRB-	16965
@NP	transplanted and control rats	16965
@NP	6 weeks	16995
@NP	SCI -LRB- A -RRB-	17009
@NP	SCI	17009
@NP	A	17014
@NP	The maximum amplitudes -LRB- μV -RRB- -LRB- B -RRB-	17018
@NP	The maximum amplitudes -LRB- μV -RRB-	17018
@NP	The maximum amplitudes	17018
@NP	μV	17042
@NP	B	17047
@NP	the latency -LRB- ms -RRB- -LRB- C -RRB- obtained from individual animals	17054
@NP	the latency -LRB- ms -RRB- -LRB- C -RRB-	17054
@NP	the latency -LRB- ms -RRB-	17054
@NP	the latency	17054
@NP	ms	17067
@NP	C	17072
@NP	individual animals	17089
@NP	a scatterplot	17121
@NP	1-week intervals following transplantation or saline injection -LRB- Tx -RRB-	17138
@NP	1-week intervals	17138
@NP	transplantation or saline injection -LRB- Tx -RRB-	17165
@NP	transplantation or saline injection	17165
@NP	Tx	17202
@NP	The linear regression lines	17207
@NP	solid lines	17248
@NP	Figure 3 .	17262
@NP	Figure	17262
@NP	3	17269
@NP	CFDA-SE-stained OEG -LRB- green -RRB- and SNARF-1-stained MSC -LRB- red -RRB-	17272
@NP	CFDA-SE-stained OEG -LRB- green -RRB-	17272
@NP	CFDA-SE-stained OEG	17272
@NP	SNARF-1-stained MSC -LRB- red -RRB-	17304
@NP	SNARF-1-stained MSC	17304
@NP	red	17325
@NP	the Methods	17335
@NP	a balloon-induced SCI 1 week after transplantation -LRB- A -RRB-	17351
@NP	a balloon-induced SCI 1 week	17351
@NP	transplantation -LRB- A -RRB-	17386
@NP	transplantation	17386
@NP	A	17403
@NP	MSC -LRB- B -RRB- and OEG -LRB- C -RRB- obtained from GFP transgenic rats	17407
@NP	MSC -LRB- B -RRB-	17407
@NP	MSC	17407
@NP	B	17412
@NP	OEG -LRB- C -RRB- obtained from GFP transgenic rats	17419
@NP	OEG -LRB- C -RRB-	17419
@NP	OEG	17419
@NP	C	17424
@NP	GFP transgenic rats	17441
@NP	brilliant green color	17468
@NP	the spinal cord 9 weeks	17493
@NP	the spinal cord	17493
@NP	9 weeks	17509
@NP	SCI	17523
@NP	MSC	17528
@NP	such long and thin processes as OEG	17545
@NP	such long and thin processes	17545
@NP	OEG	17577
@NP	OEG	17595
@NP	a conduit	17616
@NP	each other	17642
@NP	OEG expressing p75 -LRB- D -RRB-	17663
@NP	OEG	17663
@NP	p75 -LRB- D -RRB-	17678
@NP	p75	17678
@NP	D	17683
@NP	their long processes	17695
@NP	each other	17730
@NP	The balloon-compressed spinal cord	17742
@NP	copious vacuoles	17798
@NP	Corticospinal tract axons	17816
@NP	the control animals -LRB- E -RRB-	17873
@NP	the control animals	17873
@NP	E	17894
@NP	the lesioned spinal cords -LRB- arrows -RRB-	17914
@NP	the lesioned spinal cords	17914
@NP	arrows	17941
@NP	8 weeks	17949
@NP	OEG/MSC transplantation	17963
@NP	F	17988
@NP	Figure 4 .	17993
@NP	Figure	17993
@NP	4	18000
@NP	Cross-sectional areas -LRB- mm2 -RRB- of the white -LRB- A -RRB-	18003
@NP	Cross-sectional areas -LRB- mm2 -RRB-	18003
@NP	Cross-sectional areas	18003
@NP	mm2	18026
@NP	the white -LRB- A -RRB-	18034
@NP	gray -LRB- B -RRB- matter	18052
@NP	B	18058
@NP	1-mm increments	18079
@NP	the injury epicenter , which is shown as 0	18100
@NP	the injury epicenter	18100
@NP	0	18140
@NP	Numbers	18143
@NP	the distance	18160
@NP	the injury epicenter in millimeters	18178
@NP	the injury epicenter	18178
@NP	millimeters	18202
@NP	The spared areas	18215
@NP	the type of transplanted cell	18259
@NP	the type	18259
@NP	transplanted cell	18271
@NP	Figure 5 .	18291
@NP	Figure	18291
@NP	5	18298
@NP	The total volumes -LRB- mm3 -RRB- of the white and gray matter	18301
@NP	The total volumes -LRB- mm3 -RRB-	18301
@NP	The total volumes	18301
@NP	mm3	18320
@NP	the white and gray matter	18328
@NP	area measurements	18370
@NP	21-mm long segments of the lesioned spinal cord	18404
@NP	21-mm long segments	18404
@NP	the lesioned spinal cord	18427
@NP	The volume of the white matter	18453
@NP	The volume	18453
@NP	the white matter	18467
@NP	the transplanted groups	18498
@NP	the control group -LRB- A -RRB- -LRB- ∗ P < 0.05 , ∗ ∗ P < 0.01 -RRB-	18530
@NP	the control group -LRB- A -RRB-	18530
@NP	the control group	18530
@NP	A	18549
@NP	∗ P < 0.05 , ∗ ∗ P < 0.01	18553
@NP	∗ P	18553
@NP	< 0.05 , ∗ ∗ P < 0.01	18556
@NP	< 0.05 , ∗ ∗ P <	18556
@NP	<	18556
@NP	0.05	18558
@NP	∗ ∗ P	18564
@NP	0.01	18570
@NP	The gray matter	18577
@NP	well-spared in the OEG/MSC - and MSC-transplanted rats	18597
@NP	the OEG/MSC	18612
@NP	the controls -LRB- B -RRB- -LRB- ∗ ∗ P < 0.01 -RRB-	18665
@NP	the controls -LRB- B -RRB-	18665
@NP	the controls	18665
@NP	B	18679
@NP	∗ ∗ P < 0.01	18683
@NP	∗ ∗ P <	18683
@NP	∗ ∗ P	18683
@NP	<	18687
@NP	0.01	18689
@NP	The volumes -LRB- mm3 -RRB- of the white and gray matter	18696
@NP	The volumes -LRB- mm3 -RRB-	18696
@NP	The volumes	18696
@NP	mm3	18709
@NP	the white and gray matter	18717
@NP	the area	18763
@NP	2-mm cranial and caudal to the injury epicenter , where the cells were implanted	18780
@NP	2-mm cranial and caudal to the injury epicenter	18780
@NP	the injury	18807
@NP	the cells	18835
@NP	There	18861
@NP	no signifi cant difference in the white matter volume -LRB- C -RRB-	18871
@NP	no signifi cant difference	18871
@NP	the white matter volume -LRB- C -RRB-	18901
@NP	the white matter volume	18901
@NP	C	18926
@NP	the gray matter	18933
@NP	the injection sites -LRB- D -RRB- -LRB- ∗ ∗ P < 0.01 -RRB-	18986
@NP	the injection sites -LRB- D -RRB-	18986
@NP	the injection sites	18986
@NP	D	19007
@NP	∗ ∗ P < 0.01	19011
@NP	∗ ∗ P <	19011
@NP	∗ ∗ P	19011
@NP	<	19015
@NP	0.01	19017
@NP	Functional outcome BBB	19025
@NP	Hindlimb locomotion	19054
@NP	SCI	19100
@NP	an open-fi eld BBB test	19110
@NP	The animals	19135
@NP	a BBB score of 0	19151
@NP	a BBB score	19151
@NP	0	19166
@NP	the induction of the balloon compression lesion	19186
@NP	the induction	19186
@NP	the balloon compression lesion	19203
@NP	Some of the three joints in the hindlimb	19235
@NP	Some	19235
@NP	the three joints in the hindlimb	19243
@NP	the three joints	19243
@NP	the hindlimb	19263
@NP	their ability to move during the fi rst post-surgical week	19294
@NP	the fi rst	19323
@NP	post-surgical week	19334
@NP	the animals	19358
@NP	their paws	19383
@NP	the ground	19397
@NP	The control animals	19409
@NP	BBB scores of 7.08	19438
@NP	BBB scores	19438
@NP	7.08	19452
@NP	± 0.24	19457
@NP	the end	19467
@NP	the experiment -LRB- 9 weeks after SCI , 8 weeks after transplantation -RRB-	19478
@NP	the experiment	19478
@NP	9 weeks after SCI , 8 weeks after transplantation	19494
@NP	9 weeks	19494
@NP	SCI , 8 weeks after transplantation	19508
@NP	SCI	19508
@NP	8 weeks after transplantation	19513
@NP	8 weeks	19513
@NP	transplantation	19527
@NP	their body weight	19564
@NP	their hind legs	19585
@NP	the fi rst	19609
@NP	week	19620
@NP	transplantation	19631
@NP	the transplanted animals	19648
@NP	a tendency to improve their BBB scores	19688
@NP	their BBB scores	19710
@NP	the transplanted groups	19734
@NP	the fastest recovery	19759
@NP	animals transplanted with OEG	19796
@NP	animals	19796
@NP	OEG	19822
@NP	These animals	19827
@NP	signifi	19848
@NP	cant improvement	19856
@NP	the controls as early as 4 weeks after SCI -LRB- P < 0.05 -RRB-	19887
@NP	the controls	19887
@NP	early as 4 weeks	19903
@NP	SCI	19926
@NP	P < 0.05	19931
@NP	P	19931
@NP	< 0.05	19933
@NP	<	19933
@NP	0.05	19935
@NP	their fi nal BBB score	19945
@NP	their fi	19945
@NP	nal BBB score	19954
@NP	9.30 ± 0.46	19972
@NP	Animals with OEG and MSC co-grafts	19985
@NP	Animals	19985
@NP	OEG and MSC co-grafts	19998
@NP	they	20033
@NP	six injections	20047
@NP	cant	20094
@NP	ment 6 weeks after SCI , with a fi nal BBB	20107
@NP	ment	20107
@NP	6 weeks	20112
@NP	SCI	20126
@NP	a fi	20136
@NP	nal BBB	20141
@NP	9.18 ± 0.44	20158
@NP	One week	20171
@NP	i.e. 7 weeks after SCI	20187
@NP	i.e.	20187
@NP	7 weeks after SCI	20192
@NP	7 weeks	20192
@NP	SCI	20206
@NP	similar motor improvement	20212
@NP	MSC-transplanted rats -LRB- fi nal BBB score of 8.94 ± 0.42 -RRB-	20254
@NP	MSC-transplanted rats	20254
@NP	fi nal BBB score of 8.94 ± 0.42	20277
@NP	fi nal BBB score	20277
@NP	8.94 ± 0.42	20297
@NP	Figure 1A	20311
@NP	All transplanted animals	20323
@NP	their gait	20358
@NP	some of them	20370
@NP	some	20370
@NP	them	20378
@NP	their body weight	20413
@NP	paw stepping , and two animals from the OEG	20446
@NP	paw stepping	20446
@NP	paw	20446
@NP	two animals from the OEG	20464
@NP	two animals	20464
@NP	the OEG	20481
@NP	MSC-transplanted groups	20494
@NP	co-ordination of the forelimbs and hindlimbs	20525
@NP	co-ordination	20525
@NP	the forelimbs and hindlimbs	20542
@NP	conclusion	20583
@NP	there	20594
@NP	no signifi	20605
@NP	cant differences	20616
@NP	any of the transplanted animal groups in terms of overall functional	20639
@NP	any	20639
@NP	the transplanted animal groups in terms of overall functional	20646
@NP	the transplanted animal groups	20646
@NP	terms of overall functional	20680
@NP	terms	20680
@NP	overall functional	20689
@NP	overall	20689
@NP	ment	20716
@NP	the end of the experiment -LRB- P < 0.05 -RRB-	20724
@NP	the end	20724
@NP	the experiment -LRB- P < 0.05 -RRB-	20735
@NP	the experiment	20735
@NP	P < 0.05	20751
@NP	P	20751
@NP	< 0.05	20753
@NP	<	20753
@NP	0.05	20755
@NP	Plantar test The withdrawal latency	20762
@NP	Plantar test	20762
@NP	The withdrawal latency	20775
@NP	the hindpaws in response to a thermal stimulus	20801
@NP	the hindpaws	20801
@NP	response to a thermal stimulus	20817
@NP	response	20817
@NP	a thermal stimulus	20829
@NP	a week	20866
@NP	the fi rst post-operative week -LRB- before trans plantation -RRB-	20881
@NP	the fi rst post-operative week	20881
@NP	the fi rst	20881
@NP	post-operative week	20892
@NP	trans plantation	20920
@NP	the average latency	20939
@NP	hindpaw withdrawal	20962
@NP	three repeated measurements at 5-min intervals	20998
@NP	three repeated measurements	20998
@NP	5-min intervals	21029
@NP	7.18 ± 0.30	21050
@NP	7.18 ±	21050
@NP	0.30	21057
@NP	6.75 ± 0.24	21063
@NP	6.75	21063
@NP	± 0.24	21068
@NP	7.51 ± 0.27 and 7.18 ± 0.44 s , in OEG/MSC - , OEG	21076
@NP	7.51 ± 0.27	21076
@NP	7.51	21076
@NP	± 0.27	21081
@NP	7.18 ± 0.44 s , in OEG/MSC - , OEG	21092
@NP	7.18 ± 0.44 s	21092
@NP	OEG/MSC	21110
@NP	OEG	21120
@NP	MSC-transplanted rats and control rats	21129
@NP	MSC-transplanted rats	21129
@NP	control rats	21155
@NP	The latency of each group	21183
@NP	The latency	21183
@NP	each group	21198
@NP	the second week following lesion induction	21235
@NP	the second week	21235
@NP	lesion induction	21261
@NP	The control group	21279
@NP	the transplanted groups	21338
@NP	their withdrawal latency	21372
@NP	each subsequent week	21404
@NP	Signifi cant differences from the control rats -LRB- P < 0.05 -RRB-	21426
@NP	Signifi cant differences from the control rats	21426
@NP	Signifi cant differences	21426
@NP	the control rats	21456
@NP	P < 0.05	21474
@NP	P	21474
@NP	< 0.05	21476
@NP	<	21476
@NP	0.05	21478
@NP	the transplanted rats during the sixth post-surgical week	21505
@NP	the transplanted rats	21505
@NP	the sixth post-surgical week	21534
@NP	The fi nal values	21564
@NP	The fi	21564
@NP	nal values	21571
@NP	9 weeks	21593
@NP	SCI	21607
@NP	5.83	21616
@NP	± 0.25	21621
@NP	5.69 ± 0.21 and 5.42 ± 0.22 s in OEG	21629
@NP	5.69	21629
@NP	± 0.21 and 5.42 ± 0.22 s in OEG	21634
@NP	± 0.21 and 5.42 ± 0.22 s	21634
@NP	OEG	21662
@NP	OEG	21673
@NP	MSC-transplanted rats , respectively -LRB- Figure 1B -RRB- ; these	21682
@NP	MSC-transplanted rats , respectively -LRB- Figure 1B -RRB-	21682
@NP	MSC-transplanted rats , respectively	21682
@NP	MSC-transplanted rats	21682
@NP	Figure 1B	21719
@NP	these	21731
@NP	values	21737
@NP	signifi cantly different -LRB- P < 0.05 -RRB-	21749
@NP	signifi	21749
@NP	P < 0.05	21775
@NP	P	21775
@NP	< 0.05	21777
@NP	<	21777
@NP	0.05	21779
@NP	those of the control group	21790
@NP	those	21790
@NP	the control group	21799
@NP	6.72 ± 0.12 s	21818
@NP	6.72 ± 0.12	21818
@NP	6.72 ±	21818
@NP	0.12	21825
@NP	s	21830
@NP	Hyperalgesia	21834
@NP	OEG and/or MSC transplantation	21872
@NP	OEG	21872
@NP	MSC transplantation	21883
@NP	Electrophysiologic evaluation MEP	21904
@NP	the induction of the balloon compression lesion	21969
@NP	the induction	21969
@NP	the balloon compression lesion	21986
@NP	The peak amplitude of MEP	22018
@NP	The peak amplitude	22018
@NP	MEP	22040
@NP	7.19 ± 0.41 mV on average	22048
@NP	0.41 mV	22055
@NP	average	22066
@NP	intact rats	22077
@NP	the balloon	22095
@NP	saline	22126
@NP	a bursting discharge	22134
@NP	MEP	22169
@NP	1 min	22193
@NP	balloon infl ation	22205
@NP	The MEP	22225
@NP	amplitude	22258
@NP	between 5 and 15 μV	22271
@NP	the 5-min compression procedure	22298
@NP	stronger electric stimuli	22335
@NP	their amplitude	22386
@NP	the surgery	22420
@NP	MEP	22433
@NP	2 weeks to 6 weeks	22463
@NP	2 weeks	22463
@NP	6 weeks	22474
@NP	SCI	22488
@NP	Figure 2A	22493
@NP	representative MEP	22509
@NP	individual animals	22540
@NP	each group	22564
@NP	Figure 2B	22582
@NP	the maximum amplitudes recorded in all animals	22598
@NP	the maximum amplitudes	22598
@NP	all animals	22633
@NP	the type of transplanted cells	22669
@NP	the type	22669
@NP	transplanted cells	22681
@NP	OEG/MSC , OEG , MSC and control	22701
@NP	Linear regression	22732
@NP	the signifi cance of the increase in MEP amplitude	22770
@NP	the signifi cance	22770
@NP	the increase in MEP amplitude	22791
@NP	the increase	22791
@NP	MEP amplitude	22807
@NP	time	22826
@NP	There	22832
@NP	no signifi cant impact	22842
@NP	the slope	22868
@NP	the linear regression line	22881
@NP	the control rats -LRB- R2 = 0.004 , P = 0.278 -RRB-	22911
@NP	the control rats	22911
@NP	R2 = 0.004 , P = 0.278	22929
@NP	R2	22929
@NP	= 0.004 , P = 0.278	22932
@NP	= 0.004 , P	22932
@NP	0.004	22934
@NP	0.278	22945
@NP	The MEP of the control animals	22953
@NP	The MEP	22953
@NP	the control animals	22964
@NP	any improvement in amplitude	22997
@NP	any improvement	22997
@NP	amplitude	23016
@NP	between 15 and 40 μV	23041
@NP	6 weeks	23062
@NP	contrast	23090
@NP	the transplanted groups	23100
@NP	more	23131
@NP	improvement than the control group	23136
@NP	improvement	23136
@NP	the control group	23153
@NP	A signifi cant difference	23172
@NP	5 and 6 weeks after SCI	23208
@NP	5 and 6 weeks	23208
@NP	SCI	23228
@NP	2 weeks	23246
@NP	SCI -LRB- P < 0.05 -RRB- in the OEG/MSC-transplanted group	23260
@NP	SCI -LRB- P < 0.05 -RRB-	23260
@NP	SCI	23260
@NP	P < 0.05	23265
@NP	P	23265
@NP	< 0.05	23267
@NP	<	23267
@NP	0.05	23269
@NP	the OEG/MSC-transplanted group	23278
@NP	2 weeks	23321
@NP	6 weeks	23333
@NP	SCI -LRB- P < 0.01 -RRB- in the OEG-transplanted group	23347
@NP	SCI -LRB- P < 0.01 -RRB-	23347
@NP	SCI	23347
@NP	P < 0.01	23352
@NP	P	23352
@NP	< 0.01	23354
@NP	<	23354
@NP	0.01	23356
@NP	the OEG-transplanted group	23365
@NP	Linear regression analysis	23393
@NP	the weekly increases in amplitude	23432
@NP	the weekly increases	23432
@NP	amplitude	23456
@NP	statistically signifi cant	23471
@NP	the OEG/MSC -	23501
@NP	the OEG/MSC	23501
@NP	R2 = 0.122 , P	23515
@NP	R2	23515
@NP	0.122 , P	23520
@NP	0.122	23520
@NP	P	23527
@NP	0.002	23531
@NP	OEG	23539
@NP	R2 = 0.132 , P = 0.0002	23545
@NP	R2	23545
@NP	= 0.132 , P = 0.0002	23548
@NP	= 0.132 , P	23548
@NP	0.132	23550
@NP	0.0002	23561
@NP	MSC-transplanted groups -LRB- R2 = 0.037 , P = 0.038 -RRB-	23573
@NP	MSC-transplanted groups	23573
@NP	R2 = 0.037 , P = 0.038	23598
@NP	R2	23598
@NP	= 0.037 , P = 0.038	23601
@NP	= 0.037 , P	23601
@NP	0.037	23603
@NP	0.038	23614
@NP	The duration of the response and the latency to onset of the response	23622
@NP	The duration	23622
@NP	the response and the latency to onset of the response	23638
@NP	the response	23638
@NP	the latency to onset of the response	23655
@NP	the latency	23655
@NP	onset of the response	23670
@NP	onset	23670
@NP	the response	23679
@NP	5.55 ± 1.37 ms and 4.81 ± 0.67 ms in the intact animals	23697
@NP	5.55 ± 1.37 ms	23697
@NP	5.55 ±	23697
@NP	1.37 ms	23704
@NP	4.81 ± 0.67 ms in the intact animals	23716
@NP	4.81 ± 0.67 ms	23716
@NP	the intact animals	23734
@NP	The duration of MEP	23768
@NP	The duration	23768
@NP	MEP	23784
@NP	1 ms	23804
@NP	SCI	23815
@NP	The response duration of MEP	23820
@NP	The response duration	23820
@NP	MEP	23845
@NP	the OEG/MSC - and MSCtransplanted groups	23870
@NP	the OEG/MSC	23870
@NP	MSCtransplanted groups	23887
@NP	week	23935
@NP	week in the OEG-transplanted and control groups	23943
@NP	week	23943
@NP	the OEG-transplanted and control groups	23951
@NP	A difference	23992
@NP	1 week	24018
@NP	transplantation -LRB- 2 weeks after SCI -RRB-	24031
@NP	transplantation	24031
@NP	2 weeks after SCI	24048
@NP	2 weeks	24048
@NP	SCI	24062
@NP	OEG/MSC - and MSC-transplanted rats	24075
@NP	the control rats -LRB- P 0.05 ; data not shown -RRB-	24114
@NP	the control rats	24114
@NP	P 0.05 ; data not shown	24132
@NP	P 0.05	24132
@NP	data not shown	24142
@NP	data	24142
@NP	The latency	24159
@NP	normal values	24209
@NP	the experiment	24234
@NP	Linear regression analysis	24250
@NP	a tendency towards decreased latency in the transplanted groups	24286
@NP	a tendency	24286
@NP	decreased latency in the transplanted groups	24305
@NP	decreased latency	24305
@NP	the transplanted groups	24326
@NP	the slope of the linear regression line	24366
@NP	the slope	24366
@NP	the linear regression line	24379
@NP	statistically signifi cant	24410
@NP	the OEG/MSC-transplanted group -LRB- R2 0.095 , P 0.044 -RRB-	24440
@NP	the OEG/MSC-transplanted group	24440
@NP	R2 0.095	24472
@NP	P 0.044	24484
@NP	contrast	24499
@NP	there	24509
@NP	no such tendency observed in the control group -LRB- Figure 2C -RRB-	24519
@NP	no such tendency	24519
@NP	the control group -LRB- Figure 2C -RRB-	24548
@NP	the control group	24548
@NP	Figure 2C	24567
@NP	Histology Cell survival .	24579
@NP	Histology Cell	24579
@NP	survival	24594
@NP	cell survival	24615
@NP	SCI	24632
@NP	we	24637
@NP	longitudinal cryosections of the ballooncompressed spinal cord	24649
@NP	longitudinal cryosections	24649
@NP	the ballooncompressed spinal cord	24678
@NP	The green fl uorescence expressed by CFDA-SE-labeled OEG	24713
@NP	The green fl uorescence	24713
@NP	CFDA-SE-labeled OEG	24750
@NP	a fl uorescent microscope	24788
@NP	8 weeks of observation	24825
@NP	8 weeks	24825
@NP	observation	24836
@NP	transplantation	24854
@NP	SNARF-1 - or CFDA-SE-labeled MSC	24880
@NP	SNARF-1	24880
@NP	CFDA-SE-labeled MSC	24892
@NP	only 4 or 5 weeks	24929
@NP	SCI -LRB- Figure 3A -RRB-	24953
@NP	SCI	24953
@NP	Figure 3A	24958
@NP	MSC	24992
@NP	It	25011
@NP	the concentration of the	25033
@NP	the concentration	25033
@NP	the	25054
@NP	longer observation	25083
@NP	more reliable tracking of the cells in vivo	25124
@NP	more reliable tracking	25124
@NP	the cells in vivo	25150
@NP	the cells	25150
@NP	vivo	25163
@NP	OEG and MSC obtained from GFP transgenic rats	25169
@NP	OEG and MSC	25169
@NP	GFP transgenic rats	25195
@NP	long-term tracking	25229
@NP	Transplants of both types of cells	25249
@NP	Transplants	25249
@NP	both types of cells	25264
@NP	both types	25264
@NP	cells	25278
@NP	every week	25310
@NP	the same way	25324
@NP	MSC -LRB- Figure 3B -RRB- and OEG -LRB- Figure 3C -RRB-	25348
@NP	MSC -LRB- Figure 3B -RRB-	25348
@NP	MSC	25348
@NP	Figure 3B	25353
@NP	OEG -LRB- Figure 3C -RRB-	25368
@NP	OEG	25368
@NP	Figure 3C	25373
@NP	GFP rats	25389
@NP	their vivid green color	25424
@NP	the spinal cord for 8 weeks	25451
@NP	the spinal cord	25451
@NP	8 weeks	25471
@NP	None of the studied cell types	25480
@NP	None	25480
@NP	the studied cell types	25488
@NP	any extensive migration	25518
@NP	the spinal cord tissue	25549
@NP	they	25576
@NP	the injection sites	25618
@NP	the injection pressure	25667
@NP	MSC	25691
@NP	the injection sites	25709
@NP	transplantation	25735
@NP	OEG	25758
@NP	their long processes	25771
@NP	close contact	25808
@NP	one another	25827
@NP	It	25840
@NP	OEG	25858
@NP	conduits	25869
@NP	they	25882
@NP	the lamina propria in situ to ensheath and guide the olfactory axons	25893
@NP	the lamina propria	25893
@NP	to ensheath and guide the olfactory axons	25920
@NP	ensheath and guide	25923
@NP	Figure 3C	25963
@NP	Such dynamic behavior of OEG	25975
@NP	Such dynamic behavior	25975
@NP	OEG	26000
@NP	OEG	26032
@NP	each other	26055
@NP	their long processes -LRB- Figure 3D -RRB-	26078
@NP	their long processes	26078
@NP	Figure 3D	26100
@NP	the end of the experiments	26115
@NP	the end	26115
@NP	the experiments	26126
@NP	the number of surviving cells	26143
@NP	the number	26143
@NP	surviving cells	26157
@NP	There	26186
@NP	great differences between individual animals even in the same group	26197
@NP	great differences	26197
@NP	individual animals even in the same group	26223
@NP	individual animals	26223
@NP	the same group	26250
@NP	The percentage of surviving MSC and OEG was 0.41	26266
@NP	The percentage	26266
@NP	MSC and OEG	26294
@NP	0.41	26310
@NP	0.96 % and 0.34	26315
@NP	0.96 %	26315
@NP	0.34	26325
@NP	1.72 % , respectively	26330
@NP	1.72 %	26330
@NP	Similar cell survival rates	26351
@NP	the co-transplanted group	26396
@NP	Nestin and βIII-tubulin staining	26423
@NP	any positive cells	26471
@NP	the transplanted OEG or MSC 8 weeks	26496
@NP	the transplanted OEG	26496
@NP	MSC 8 weeks	26520
@NP	MSC	26520
@NP	8 weeks	26524
@NP	transplantation	26538
@NP	Morphometric evaluation The area of the spinal cord	26555
@NP	Morphometric evaluation The area	26555
@NP	the spinal cord	26591
@NP	serial cross-sections	26627
@NP	1-cm cranial and 1-cm caudal	26649
@NP	the injury epicenter , which was identifi	26683
@NP	the injury epicenter	26683
@NP	the thinnest part of the thoracic spinal cord	26730
@NP	the thinnest part	26730
@NP	the thoracic spinal cord	26751
@NP	The crosssectional areas -LRB- mm2 -RRB- of the white and gray matter	26777
@NP	The crosssectional areas -LRB- mm2 -RRB-	26777
@NP	The crosssectional areas	26777
@NP	mm2	26803
@NP	the white and gray matter	26811
@NP	1-mm increments	26853
@NP	the injury epicenter -LRB- Figure 4A , B -RRB-	26874
@NP	the injury epicenter	26874
@NP	Figure 4A , B	26896
@NP	Figure 4A	26896
@NP	B	26907
@NP	The cross-sectional area of the spared white and gray matter	26911
@NP	The cross-sectional area	26911
@NP	the spared white and gray matter	26939
@NP	any 1-mm distant sectional point in the control group	26994
@NP	any 1-mm distant sectional point	26994
@NP	the control group	27030
@NP	the transplanted groups	27056
@NP	some of differences in area	27085
@NP	some	27085
@NP	differences in area	27093
@NP	differences	27093
@NP	area	27108
@NP	statistical signifi cance	27121
@NP	the total volume of the white and gray matter -LRB- mm3 -RRB-	27153
@NP	the total volume	27153
@NP	the white and gray matter -LRB- mm3 -RRB-	27173
@NP	the white and gray matter	27173
@NP	mm3	27200
@NP	area measurements	27225
@NP	21-mm long segments	27259
@NP	a larger volume of spared white matter	27280
@NP	a larger volume	27280
@NP	spared white matter	27299
@NP	rats	27335
@NP	any type	27355
@NP	cell -LRB- 36.9 ± 1.9 mm3 , 38.8 ± 1.2 mm3 and 38.9 ± 0.8 mm3 in the OEG /	27367
@NP	cell -LRB- 36.9 ± 1.9 mm3	27367
@NP	cell	27367
@NP	36.9 ± 1.9 mm3	27373
@NP	36.9 ±	27373
@NP	1.9 mm3	27380
@NP	±	27394
@NP	1.2 mm3	27396
@NP	± 0.8 mm3 in the OEG	27413
@NP	± 0.8 mm3	27413
@NP	the OEG	27426
@NP	OEG	27441
@NP	MSC-transplanted rats , respectively -RRB-	27450
@NP	MSC-transplanted rats	27450
@NP	30.7 ± 0.9 mm3 in the control animals -LRB- P < 0.05 ; Figure 5A -RRB-	27501
@NP	30.7 ± 0.9 mm3 in the control animals	27501
@NP	0.9 mm3	27508
@NP	the control animals	27519
@NP	P < 0.05 ; Figure 5A	27540
@NP	P	27540
@NP	< 0.05 ; Figure 5A	27542
@NP	< 0.05	27542
@NP	<	27542
@NP	0.05	27544
@NP	Figure 5A	27550
@NP	Figure	27550
@NP	5A	27557
@NP	The volume of gray matter calculated from 21-mm long segments	27562
@NP	The volume	27562
@NP	gray matter calculated from 21-mm long segments	27576
@NP	gray matter	27576
@NP	21-mm long segments	27604
@NP	OEG/MSC and MSC transplants	27638
@NP	terms of gray matter sparing -LRB- Figure 5B ; P < 0.01 -RRB-	27689
@NP	terms	27689
@NP	gray matter sparing -LRB- Figure 5B ; P < 0.01 -RRB-	27698
@NP	gray matter sparing	27698
@NP	Figure 5B ; P < 0.01	27719
@NP	Figure 5B	27719
@NP	P < 0.01	27730
@NP	P <	27730
@NP	P	27730
@NP	0.01	27734
@NP	the volume of the spared white and gray matter	27746
@NP	the volume	27746
@NP	the spared white and gray matter	27760
@NP	the cranial half and caudal half segments	27814
@NP	the cranial half	27814
@NP	caudal half segments	27835
@NP	the injury epicenter	27861
@NP	a signifi cant difference in the volume of the white matter	27883
@NP	a signifi cant difference	27883
@NP	the volume of the white matter	27912
@NP	the volume	27912
@NP	the white matter	27926
@NP	the caudal segments	27956
@NP	OEG-transplanted rats and control rats -LRB- P < 0.05 -RRB-	27984
@NP	OEG-transplanted rats and control rats	27984
@NP	P < 0.05	28024
@NP	P	28024
@NP	< 0.05	28026
@NP	<	28026
@NP	0.05	28028
@NP	The white matter	28035
@NP	the thoracic segments	28073
@NP	the injury epicenter in OEG-transplanted rats , while in OEG / MSC	28105
@NP	the injury epicenter	28105
@NP	OEG-transplanted rats	28129
@NP	OEG	28161
@NP	MSC-transplanted rats	28175
@NP	the white matter	28197
@NP	the cranial and caudal segments	28239
@NP	the other hand	28275
@NP	the gray matter	28291
@NP	cranial segments in both OEG/MSCand MSC-transplanted animals	28326
@NP	cranial segments in both OEG/MSCand	28326
@NP	cranial segments	28326
@NP	both OEG/MSCand	28346
@NP	P < 0.05	28388
@NP	P	28388
@NP	< 0.05	28390
@NP	<	28390
@NP	0.05	28392
@NP	The volume	28399
@NP	the gray matter	28413
@NP	the area between 2-mm cranial and 2-mm caudal	28444
@NP	the area	28444
@NP	2-mm cranial and 2-mm caudal	28461
@NP	the injury epicenter	28493
@NP	the cells	28521
@NP	the gray matter	28562
@NP	the injection sites -LRB- Figure 5C , D -RRB-	28608
@NP	the injection sites	28608
@NP	Figure 5C , D	28629
@NP	Figure 5C	28629
@NP	D	28640
@NP	The volume of the gray matter in the transplanted animals	28644
@NP	The volume	28644
@NP	the gray matter in the transplanted animals	28658
@NP	the gray matter	28658
@NP	the transplanted animals	28677
@NP	signifi cantly different from that in the control animals -LRB- P < 0.01 -RRB-	28706
@NP	signifi cantly different from that in the control animals	28706
@NP	that in the control	28736
@NP	that	28736
@NP	the control	28744
@NP	P < 0.01	28765
@NP	P	28765
@NP	< 0.01	28767
@NP	<	28767
@NP	0.01	28769
@NP	Anterograde tracing	28776
@NP	Anterograde	28776
@NP	a larger volume of the white matter	28816
@NP	a larger volume	28816
@NP	the white matter	28835
@NP	the corticospinal axons	28864
@NP	the spared white matter -LRB- Figure 3F -RRB-	28909
@NP	the spared white matter	28909
@NP	Figure 3F	28934
@NP	Axons	28946
@NP	the injury epicenter in the control rats -LRB- Figure 3E -RRB-	28978
@NP	the injury epicenter	28978
@NP	the control rats -LRB- Figure 3E -RRB-	29002
@NP	the control rats	29002
@NP	Figure 3E	29020
@NP	Discussion The subacute phase , up to 3 -- 4 weeks after SCI ,	29033
@NP	Discussion The subacute phase , up to 3	29033
@NP	Discussion	29033
@NP	The subacute phase	29044
@NP	3	29070
@NP	4 weeks after SCI	29072
@NP	4 weeks	29072
@NP	SCI	29086
@NP	the therapeutic window for cell therapy	29094
@NP	the therapeutic window	29094
@NP	cell therapy	29121
@NP	humans	29137
@NP	animal models -LRB- 30 -RRB-	29158
@NP	animal models	29158
@NP	30	29173
@NP	Cell survival	29178
@NP	the cells	29207
@NP	the subacute phase	29237
@NP	the acute phase of SCI -LRB- 31 -RRB-	29271
@NP	the acute phase	29271
@NP	SCI -LRB- 31 -RRB-	29290
@NP	SCI	29290
@NP	31	29295
@NP	Cells	29300
@NP	SCI	29337
@NP	a hostile environment characterized by infl ammation	29351
@NP	a hostile environment	29351
@NP	infl ammation	29390
@NP	the up-regulation	29405
@NP	pro-infl ammatory cytokines	29426
@NP	tumor necrosis factor-alpha , interleukin-1-beta	29455
@NP	tumor necrosis factor-alpha	29455
@NP	interleukin-1-beta	29484
@NP	ischemia , toxic substances such as free radicals	29505
@NP	ischemia	29505
@NP	toxic substances such as free radicals	29515
@NP	toxic substances	29515
@NP	free radicals	29540
@NP	the loss of ionic homeostasis -LRB- 32 -RRB-	29558
@NP	the loss	29558
@NP	ionic homeostasis -LRB- 32 -RRB-	29570
@NP	ionic homeostasis	29570
@NP	32	29589
@NP	the subacute phase	29597
@NP	phagocytosis	29617
@NP	a supportive environment	29670
@NP	neural sprouting by removing cell debris	29699
@NP	neural	29699
@NP	cell debris	29728
@NP	inhibitory components	29751
@NP	axonal growth such as CSPG and myelin-associated glycoprotein -LRB- 33 -RRB-	29777
@NP	axonal growth	29777
@NP	CSPG and myelin-associated glycoprotein -LRB- 33 -RRB-	29799
@NP	CSPG	29799
@NP	myelin-associated glycoprotein -LRB- 33 -RRB-	29808
@NP	myelin-associated glycoprotein	29808
@NP	33	29840
@NP	CSPG production	29850
@NP	SCI	29895
@NP	spontaneous recovery	29900
@NP	CSPG	29935
@NP	a benefi cial effect on the injured spinal cord in the acute phase	29955
@NP	a benefi cial effect	29955
@NP	the injured spinal cord in the acute phase	29979
@NP	the injured spinal cord	29979
@NP	the acute phase	30006
@NP	microglia and macrophages -LRB- 34 -RRB-	30036
@NP	microglia and macrophages	30036
@NP	34	30063
@NP	the inhibitory regulation of microglial activity	30077
@NP	the inhibitory regulation	30077
@NP	microglial activity	30106
@NP	the later phase of SCI	30141
@NP	the later phase	30141
@NP	SCI	30160
@NP	neural cell damage proceeds as a result of cytokines	30172
@NP	neural cell damage proceeds	30172
@NP	a result of cytokines	30203
@NP	a result	30203
@NP	cytokines	30215
@NP	free radicals released from proliferating microglia -LRB- 35 -RRB-	30229
@NP	free radicals	30229
@NP	proliferating microglia -LRB- 35 -RRB-	30257
@NP	proliferating microglia	30257
@NP	35	30282
@NP	OEG and MSC	30292
@NP	7 days	30325
@NP	SCI in our study	30338
@NP	SCI	30338
@NP	our study	30345
@NP	agreement with previous studies -LRB- 19 -RRB-	30359
@NP	agreement	30359
@NP	previous studies -LRB- 19 -RRB-	30374
@NP	previous studies	30374
@NP	19	30392
@NP	our results	30397
@NP	hindlimb locomotion	30419
@NP	OEG - and MSC-transplanted rats	30451
@NP	their co-transplantation	30492
@NP	additive and synergistic functional improvements	30539
@NP	OEG and MSC	30589
@NP	a propensity to migrate towards an injury site -LRB- 36 -- 38 -RRB-	30616
@NP	an injury site -LRB- 36 -- 38 -RRB-	30648
@NP	an injury site	30648
@NP	36 -- 38	30664
@NP	36	30664
@NP	38	30667
@NP	The GFP OEG and MSC transplants	30672
@NP	The GFP OEG	30672
@NP	MSC transplants	30688
@NP	the injection sites	30739
@NP	our experiments	30763
@NP	OEG and MSC	30780
@NP	the lesions	30813
@NP	they	30829
@NP	any considerable distance	30860
@NP	the other hand	30890
@NP	their poor migration	30906
@NP	one of the features of OEG obtained from the lamina propria -LRB- 39 -RRB-	30936
@NP	one	30936
@NP	the features of OEG obtained from the lamina propria -LRB- 39 -RRB-	30943
@NP	the features	30943
@NP	OEG obtained from the lamina propria -LRB- 39 -RRB-	30959
@NP	OEG	30959
@NP	the lamina propria -LRB- 39 -RRB-	30977
@NP	the lamina propria	30977
@NP	39	30997
@NP	Su et al. -LRB- 40 -RRB-	31002
@NP	Su et al.	31002
@NP	40	31013
@NP	post-injury upregulation of Nogo-A on oligodendrocytes	31032
@NP	post-injury upregulation	31032
@NP	Nogo-A on oligodendrocytes	31060
@NP	Nogo-A	31060
@NP	oligodendrocytes	31070
@NP	the adhesion of OEG via activation of Rho-A	31096
@NP	the adhesion	31096
@NP	OEG via activation of Rho-A	31112
@NP	OEG	31112
@NP	activation of Rho-A	31120
@NP	activation	31120
@NP	Rho-A	31134
@NP	their migration	31152
@NP	The increased activation of Rho after SCI -LRB- 41,42 -RRB-	31169
@NP	The increased activation of Rho after SCI	31169
@NP	The increased activation	31169
@NP	Rho	31197
@NP	SCI	31207
@NP	41,42	31212
@NP	the formation of MSC focal adhesions -LRB- 43,44 -RRB-	31232
@NP	the formation	31232
@NP	MSC focal adhesions -LRB- 43,44 -RRB-	31249
@NP	MSC focal adhesions	31249
@NP	43,44	31270
@NP	Poor cell migration	31278
@NP	the concerted actions	31319
@NP	OEG and MSC	31344
@NP	separate injections in our experiments	31381
@NP	separate injections	31381
@NP	our experiments	31404
@NP	Pre-treatment with a Rho antagonist or a Rho kinase inhibitor	31421
@NP	Pre-treatment	31421
@NP	a Rho antagonist or a Rho kinase inhibitor	31440
@NP	a Rho antagonist	31440
@NP	a Rho kinase inhibitor	31460
@NP	the co-transplantation of OEG and MSC	31508
@NP	the co-transplantation	31508
@NP	OEG and MSC	31534
@NP	cell migration	31560
@NP	axonal growth	31594
@NP	apoptosis	31620
@NP	the injured spinal cord -LRB- 40,45 -RRB-	31633
@NP	the injured spinal cord	31633
@NP	40,45	31658
@NP	SCI	31675
@NP	cell therapy	31680
@NP	a hostile niche	31715
@NP	neuronal sparing and regeneration	31735
@NP	the prevention of scar formation , inhibitory factors and demyelination	31780
@NP	the prevention	31780
@NP	scar formation , inhibitory factors and demyelination	31798
@NP	scar formation	31798
@NP	inhibitory factors	31814
@NP	demyelination	31837
@NP	new neural circuits	31869
@NP	the injured sites	31899
@NP	SCI	31924
@NP	the severed axons	31929
@NP	collaterals into the gray matter	31963
@NP	collaterals	31963
@NP	the gray matter	31980
@NP	46 -- 48	31997
@NP	46	31997
@NP	48	32000
@NP	new circuits	32008
@NP	propriospinal neurons in the incompletely damaged spinal cord -LRB- 49,50 -RRB-	32037
@NP	propriospinal neurons	32037
@NP	the incompletely damaged spinal cord -LRB- 49,50 -RRB-	32062
@NP	the incompletely damaged spinal cord	32062
@NP	49,50	32100
@NP	Functional recovery	32108
@NP	this newly established route	32154
@NP	The MEP	32184
@NP	a week	32206
@NP	very variable amplitudes	32220
@NP	each group and even	32248
@NP	the same animal	32271
@NP	The positions of the electrode for recording	32288
@NP	The positions	32288
@NP	the electrode for recording	32305
@NP	the electrode	32305
@NP	recording	32323
@NP	the same for every measurement	32350
@NP	the same	32350
@NP	every measurement	32363
@NP	permanent implantation	32393
@NP	electrodes into the muscle -LRB- 51 -RRB- or spinal cord -LRB- 52 -RRB-	32419
@NP	electrodes	32419
@NP	the muscle -LRB- 51 -RRB- or spinal cord -LRB- 52 -RRB-	32435
@NP	the muscle	32435
@NP	51	32447
@NP	spinal cord	32454
@NP	52	32467
@NP	periodic recordings	32496
@NP	a long-term experiment	32523
@NP	they	32549
@NP	the animal 's locomotion and behavior	32568
@NP	the animal 's	32568
@NP	the MEP	32618
@NP	variable amplitudes	32630
@NP	microvolt-levels	32670
@NP	the trend	32688
@NP	their increasing amplitude	32701
@NP	a 1-month observation period	32745
@NP	statistically signifi cant in the transplanted groups	32779
@NP	statistically signifi cant	32779
@NP	the transplanted groups	32809
@NP	The control group	32834
@NP	any improvement in amplitude	32865
@NP	any improvement	32865
@NP	amplitude	32884
@NP	the transplanted groups	32899
@NP	their amplitude	32932
@NP	week	32948
@NP	week	32956
@NP	the OEG-transplanted group	32977
@NP	the greatest improvement among the transplanted groups	33011
@NP	the greatest improvement	33011
@NP	the transplanted groups	33042
@NP	The latency of MEP	33067
@NP	The latency	33067
@NP	MEP	33082
@NP	normal values	33124
@NP	incomplete SCI	33144
@NP	another study	33189
@NP	53	33204
@NP	neural circuits	33217
@NP	the incompletely damaged spinal cord	33257
@NP	a tendency towards shortened -LRB- improved -RRB- latency	33304
@NP	a tendency towards shortened -LRB- improved -RRB-	33304
@NP	a tendency	33304
@NP	shortened -LRB- improved -RRB-	33323
@NP	latency	33344
@NP	the transplanted groups	33373
@NP	Our results	33398
@NP	the spared and recovered circuits for locomotor activity	33423
@NP	the	33423
@NP	circuits for locomotor activity	33448
@NP	circuits	33448
@NP	locomotor activity	33461
@NP	high MEP amplitudes	33506
@NP	such weak signal improvement	33536
@NP	weight-supported stepping	33581
@NP	weight-supported	33581
@NP	co-ordination between the forelimbs and hindlimbs in some cases	33611
@NP	co-ordination	33611
@NP	the forelimbs and hindlimbs in some cases	33633
@NP	the forelimbs and hindlimbs	33633
@NP	some cases	33664
@NP	This	33676
@NP	histologic fi ndings of residual axons in the spinal cord	33698
@NP	histologic fi ndings	33698
@NP	residual axons in the spinal cord	33722
@NP	residual axons	33722
@NP	the spinal cord	33740
@NP	Fehlings and Tator -LRB- 54 -RRB-	33757
@NP	Fehlings and Tator	33757
@NP	Fehlings	33757
@NP	Tator	33770
@NP	54	33777
@NP	12 % of axons	33792
@NP	12 %	33792
@NP	axons	33799
@NP	the spinal cord	33817
@NP	SCI and sustained neurologic function	33839
@NP	SCI	33839
@NP	sustained neurologic function	33847
@NP	rats	33880
@NP	The initial mechanical trauma and subsequent infl ammatory processes	33886
@NP	The initial mechanical trauma	33886
@NP	subsequent infl ammatory processes	33920
@NP	the apoptosis	33963
@NP	oligodendrocytes , which results in demyelination -LRB- 55,56 -RRB-	33980
@NP	oligodendrocytes	33980
@NP	demyelination -LRB- 55,56 -RRB-	34015
@NP	demyelination	34015
@NP	55,56	34030
@NP	OEG remyelinate	34038
@NP	axons	34067
@NP	SCI	34079
@NP	themselves -LRB- 57 -RRB-	34093
@NP	themselves	34093
@NP	57	34105
@NP	the entry of host Schwann cells	34128
@NP	the entry	34128
@NP	host Schwann cells	34141
@NP	the injured spinal cord -LRB- 58 -RRB-	34165
@NP	the injured spinal cord	34165
@NP	58	34190
@NP	The tendency towards shorter MEP latencies	34195
@NP	The tendency	34195
@NP	shorter MEP latencies	34216
@NP	signifi cant only in the co-transplanted group	34242
@NP	signifi cant	34242
@NP	the co-transplanted group	34263
@NP	The remyelination process	34290
@NP	this functional improvement	34344
@NP	Sensory afferent inputs	34373
@NP	an important role in more sophisticated locomotion -LRB- 59 -RRB-	34402
@NP	an important role	34402
@NP	more sophisticated locomotion -LRB- 59 -RRB-	34423
@NP	more sophisticated locomotion	34423
@NP	59	34454
@NP	None of the transplanted rats	34459
@NP	None	34459
@NP	the transplanted rats	34467
@NP	a BBB score	34498
@NP	15 , which requires parallel paw position during locomotion	34522
@NP	15	34522
@NP	parallel paw position	34541
@NP	locomotion	34570
@NP	The animals	34582
@NP	their paw position	34612
@NP	sensory information	34647
@NP	the paw	34672
@NP	the fl oor	34712
@NP	Our results	34724
@NP	the same clear improvement	34749
@NP	the Plantar test	34779
@NP	a previous study where MSC were implanted intravenously -LRB- 19 -RRB-	34815
@NP	a previous study	34815
@NP	MSC	34838
@NP	19	34872
@NP	intraspinal injection	34885
@NP	additional damage	34917
@NP	the dorsal columns	34938
@NP	the results from the Plantar test	34958
@NP	the results	34958
@NP	the Plantar test	34975
@NP	the present study	35018
@NP	our previous MSC study	35042
@NP	the transplantation of both types of cells	35075
@NP	the transplantation	35075
@NP	both types of cells	35098
@NP	both types	35098
@NP	cells	35112
@NP	similar results	35125
@NP	their mechanisms of action	35142
@NP	their mechanisms	35142
@NP	action	35162
@NP	the damaged spinal cord	35196
@NP	It	35221
@NP	intravenous injection	35244
@NP	MSC 7 days after SCI improves locomotor activity and signifi cantly	35269
@NP	MSC	35269
@NP	7 days	35273
@NP	SCI	35286
@NP	locomotor activity and signifi	35299
@NP	white matter	35354
@NP	the lesion area	35370
@NP	19	35387
@NP	no sparing of gray matter	35401
@NP	no sparing	35401
@NP	gray matter	35415
@NP	MSC	35441
@NP	immunomodulatory effects -LRB- 60 -RRB-	35463
@NP	immunomodulatory effects	35463
@NP	60	35489
@NP	their systemic injection	35505
@NP	uence	35539
@NP	the levels of pro- and anti-infl ammatory cytokines	35545
@NP	the levels	35545
@NP	pro- and anti-infl ammatory cytokines	35559
@NP	this	35602
@NP	a trophic effect on functional recovery	35623
@NP	a trophic effect	35623
@NP	functional recovery	35643
@NP	the lesion	35670
@NP	7 days	35707
@NP	SCI	35720
@NP	the MSC	35728
@NP	a neuroprotective agent	35747
@NP	The slow improvement observed in the Plantar test	35772
@NP	The slow improvement	35772
@NP	the Plantar test	35805
@NP	these different routes of cell injection : intraspinal versus intravenous	35852
@NP	these different routes of cell injection	35852
@NP	these different routes	35852
@NP	cell injection	35878
@NP	intraspinal versus intravenous	35894
@NP	intraspinal	35894
@NP	intravenous	35913
@NP	Cell counts	35926
@NP	the poor survival of OEG and MSC	35945
@NP	the poor survival	35945
@NP	OEG and MSC	35966
@NP	the lesioned area	35993
@NP	The direct injection of each cell type	36012
@NP	The direct injection	36012
@NP	each cell type	36036
@NP	the gray matter	36058
@NP	our study	36077
@NP	the injury epicenter	36092
@NP	a habitable environment for transplanted cells -LRB- 31 -RRB-	36120
@NP	a habitable environment	36120
@NP	transplanted cells -LRB- 31 -RRB-	36148
@NP	transplanted cells	36148
@NP	31	36168
@NP	Subarachnoid injection	36173
@NP	an alternate and promising route for cell administration	36199
@NP	an alternate and promising route	36199
@NP	cell administration	36236
@NP	additional damage	36274
@NP	the spinal cord	36295
@NP	more effi cient cell delivery	36322
@NP	the spinal cord -LRB- 61,62 -RRB-	36355
@NP	the spinal cord	36355
@NP	61,62	36372
@NP	further study	36384
@NP	the environment in the cerebrospinal fl uid -LRB- CSF -RRB-	36423
@NP	the environment	36423
@NP	the cerebrospinal fl uid -LRB- CSF -RRB-	36442
@NP	the cerebrospinal fl uid	36442
@NP	CSF	36468
@NP	transplanted cells	36477
@NP	MSC	36497
@NP	the fourth ventricle	36515
@NP	the subarachnoid space in the spinal cord	36569
@NP	the subarachnoid space	36569
@NP	the spinal cord	36595
@NP	the CSF	36619
@NP	behavioral recovery	36640
@NP	SCI	36666
@NP	these MSC	36675
@NP	3 weeks after injection	36704
@NP	3 weeks	36704
@NP	injection	36718
@NP	an immunosuppressant -LRB- 63 -RRB-	36740
@NP	an immunosuppressant	36740
@NP	63	36762
@NP	Repeated subarachnoid administration of cells	36767
@NP	Repeated subarachnoid administration	36767
@NP	cells	36807
@NP	the long-term effects of the transplanted cells on the damaged host tissue	36845
@NP	the long-term effects	36845
@NP	the transplanted cells on the damaged host tissue	36870
@NP	the transplanted cells	36870
@NP	the damaged host tissue	36896
@NP	Vanicky et al. -LRB- 21 -RRB-	36921
@NP	Vanicky et al.	36921
@NP	Vanicky	36921
@NP	et al.	36929
@NP	21	36937
@NP	balloon compression	36953
@NP	a complete loss	36982
@NP	gray matter , a partial loss of white matter and copious vacuoles	37001
@NP	gray matter	37001
@NP	a partial loss of white matter	37014
@NP	a partial loss	37014
@NP	white matter	37032
@NP	copious vacuoles	37049
@NP	Our morphometric analysis	37067
@NP	the cross-sectional area of the gray matter around the injury epicenter	37112
@NP	the cross-sectional area	37112
@NP	the gray matter around the injury epicenter	37140
@NP	the gray matter	37140
@NP	the injury epicenter	37163
@NP	0 -- 0.013 mm2 in the control animals	37188
@NP	0	37188
@NP	0.013 mm2 in the control animals	37190
@NP	0.013 mm2	37190
@NP	the control animals	37203
@NP	the gray matter	37233
@NP	the treated animals	37275
@NP	The white matter	37296
@NP	the lesioned spinal cord with the OEG/MSC and MSC transplants	37335
@NP	the lesioned spinal cord	37335
@NP	the OEG/MSC and MSC transplants	37365
@NP	OEG transplants	37404
@NP	the white matter	37430
@NP	the caudal segments	37450
@NP	the cranial segments	37483
@NP	The gray matter	37505
@NP	a greater extent	37535
@NP	the MSC	37555
@NP	and MSC-transplanted rats , especially in the spinal cord cranial	37569
@NP	MSC-transplanted rats	37573
@NP	the spinal cord	37610
@NP	the injury epicenter	37637
@NP	other words	37662
@NP	the gray matter sparing	37675
@NP	the gray matter	37675
@NP	the aid of MSC transplantation	37713
@NP	the aid	37713
@NP	MSC transplantation	37724
@NP	the white matter sparing resulting from OEG transplantation	37751
@NP	the white matter	37751
@NP	OEG transplantation	37791
@NP	spinal tract axons	37832
@NP	degeneration	37856
@NP	the early stages	37876
@NP	SCI	37896
@NP	turn	37910
@NP	the faster recovery of simple locomotor function	37929
@NP	the faster recovery	37929
@NP	simple locomotor function	37952
@NP	the volume between 2-mm cranial and 2-mm caudal	38000
@NP	the volume	38000
@NP	2-mm cranial and 2-mm caudal	38019
@NP	the injury epicenter , where the OEG and/or MSC were mainly implanted	38051
@NP	the injury epicenter	38051
@NP	the OEG and/or MSC	38079
@NP	the OEG	38079
@NP	MSC	38094
@NP	there	38121
@NP	no statistical difference	38131
@NP	the volume of the white matter between the transplanted and control groups	38160
@NP	the volume	38160
@NP	the white matter between the transplanted and control groups	38174
@NP	the white matter between the transplanted	38174
@NP	the white matter	38174
@NP	the transplanted	38199
@NP	control groups	38220
@NP	contrast	38239
@NP	a signifi cant difference	38249
@NP	the volume of the gray matter	38288
@NP	the volume	38288
@NP	the gray matter	38302
@NP	OEG and MSC	38319
@NP	the ability to spare the white and gray matter in the injured spinal cord	38335
@NP	the white and gray matter in the injured spinal cord	38356
@NP	the white and gray matter	38356
@NP	the injured spinal cord	38385
@NP	the gray matter	38425
@NP	the damaged area of the spinal cord	38467
@NP	the damaged area	38467
@NP	the spinal cord	38487
@NP	the transplants	38509
@NP	The gray matter	38549
@NP	metabolic damage than white matter	38588
@NP	metabolic damage	38588
@NP	white matter	38610
@NP	Balloon compression	38624
@NP	ischemic damage	38653
@NP	the spinal cord	38672
@NP	metabolic failure in the gray matter	38701
@NP	metabolic failure	38701
@NP	the gray matter	38722
@NP	We	38739
@NP	the transplants	38754
@NP	the gray matter	38777
@NP	such damage	38798
@NP	OEG and/or MSC treatment	38819
@NP	OEG	38819
@NP	MSC treatment	38830
@NP	the gray matter	38845
@NP	the white matter	38883
@NP	OEG and MSC	38919
@NP	more descending and ascending axons by sparing the white matter	38948
@NP	more	38948
@NP	axons	38978
@NP	the white matter	38995
@NP	they	39024
@NP	lost connections	39075
@NP	collaterals	39103
@NP	the spared axons	39120
@NP	the gray matter , which was also spared by the transplants	39140
@NP	the gray matter	39140
@NP	the transplants	39182
@NP	the gray matter	39202
@NP	interneurons	39219
@NP	neural connections	39261
@NP	the PNS and CNS	39285
@NP	OEG and/or MSC	39305
@NP	OEG	39305
@NP	MSC	39316
@NP	the animals	39340
@NP	the ability to support their body weight on their hind legs	39365
@NP	their body weight	39388
@NP	their hind legs	39409
@NP	we	39435
@NP	any unambiguous relationship	39454
@NP	the volume of the spared spinal cord tissue and behavioral improvement	39491
@NP	the volume	39491
@NP	the spared spinal cord tissue and behavioral improvement	39505
@NP	the spared spinal cord tissue	39505
@NP	behavioral improvement	39539
@NP	Functional recovery	39563
@NP	the viewpoint of synaptic reconstruction	39607
@NP	the viewpoint	39607
@NP	synaptic reconstruction	39624
@NP	the white and gray matter sparing induced by transplantation	39653
@NP	the white and gray matter sparing	39653
@NP	transplantation	39698
@NP	the feasibility of this reconstruction	39724
@NP	the feasibility	39724
@NP	this reconstruction	39743
@NP	MSC	39773
@NP	mesodermal and non-mesodermal lineages -LRB- 64 -RRB-	39821
@NP	mesodermal and non-mesodermal lineages	39821
@NP	64	39861
@NP	they	39866
@NP	the mesodermal lineage	39903
@NP	Their potential to differentiate into neuronal cells	39927
@NP	Their potential	39927
@NP	neuronal cells	39965
@NP	controversial -LRB- 65,66 -RRB-	40003
@NP	controversial	40003
@NP	65,66	40018
@NP	our experiment	40029
@NP	nestin-positive and βIII-tubulin-positive transplanted cells	40045
@NP	nestin-positive	40045
@NP	βIII-tubulin-positive transplanted cells	40065
@NP	2 months	40121
@NP	transplantation	40136
@NP	we	40162
@NP	the possibility of neural differentiation	40180
@NP	the possibility	40180
@NP	neural differentiation	40199
@NP	the transplanted cells , which might help to bridge the damaged neural circuits	40225
@NP	the transplanted cells	40225
@NP	the damaged neural circuits	40276
@NP	the trophic effects of the transplanted cells on the resident neurons	40305
@NP	the trophic effects	40305
@NP	the transplanted cells on the resident neurons	40328
@NP	the transplanted cells	40328
@NP	the resident neurons	40354
@NP	functional improvement	40401
@NP	neural damage than the possible differentiation of the transplanted cells	40441
@NP	neural damage	40441
@NP	the possible differentiation of the transplanted cells	40460
@NP	the possible differentiation	40460
@NP	the transplanted cells	40492
@NP	67	40516
@NP	OEG and MSC	40526
@NP	locomotor function	40551
@NP	the spinal cord	40581
@NP	their combined advantages	40602
@NP	no added benefi t	40636
@NP	SCI therapy	40657
@NP	Additional treatment	40670
@NP	their migration	40723
@NP	co-operation	40751
@NP	the two types of cells , or different combinations of transplants	40767
@NP	the two types of cells	40767
@NP	the two types	40767
@NP	cells	40784
@NP	different combinations of transplants	40794
@NP	different combinations	40794
@NP	transplants	40820
@NP	trophic factors might need to be considered for further functional improvement	40839
@NP	trophic factors	40839
@NP	further functional improvement	40887
@NP	a previous study	40922
@NP	the intravenous injection of MSC	40940
@NP	the intravenous injection	40940
@NP	MSC	40969
@NP	the white matter	40980
@NP	SCI , but not the gray matter -LRB- 19 -RRB-	41003
@NP	SCI	41003
@NP	the gray matter -LRB- 19 -RRB-	41016
@NP	the gray matter	41016
@NP	19	41033
@NP	the spared volume	41048
@NP	white and gray matter	41069
@NP	the intravenous injection	41099
@NP	our previous study	41133
@NP	the intraspinal injection of MSC used in the current study	41156
@NP	the intraspinal injection	41156
@NP	MSC used in the current study	41185
@NP	MSC	41185
@NP	the current study	41197
@NP	we	41216
@NP	signifi cantly more gray	41225
@NP	signifi	41225
@NP	intraspinal injection	41275
@NP	the spared volume in the control animals	41301
@NP	the spared volume	41301
@NP	the control animals	41322
@NP	100 %	41356
@NP	the spared volume of the white matter following intravenous injection	41362
@NP	the spared volume	41362
@NP	the white matter following intravenous injection	41383
@NP	the white matter	41383
@NP	intravenous injection	41410
@NP	150 % and 134 %	41436
@NP	intra spinal injection	41460
@NP	the spared volume of the gray matter	41490
@NP	the spared volume	41490
@NP	the gray matter	41511
@NP	137 % following intravenous injection and 220 % following intraspinal injection	41531
@NP	137 %	41531
@NP	intravenous injection and 220 % following intraspinal injection	41546
@NP	intravenous injection	41546
@NP	220 % following intraspinal injection	41572
@NP	220 %	41572
@NP	intraspinal injection	41587
@NP	addition	41613
@NP	recovery in the BBB test	41623
@NP	recovery	41623
@NP	the BBB test	41635
@NP	the fi rst	41667
@NP	few weeks	41678
@NP	those animals that received OEG transplants	41705
@NP	those animals	41705
@NP	OEG transplants	41733
@NP	we	41766
@NP	the advantageous effects of co-transplantation , direct implantation of OEG	41796
@NP	the advantageous effects	41796
@NP	co-transplantation , direct implantation of OEG	41824
@NP	co-transplantation	41824
@NP	direct implantation of OEG	41844
@NP	direct implantation	41844
@NP	OEG	41867
@NP	the spinal cord lesion accompanied by intravenous injection of MSC	41876
@NP	the spinal cord lesion	41876
@NP	intravenous injection of MSC	41914
@NP	intravenous injection	41914
@NP	MSC	41939
@NP	another , perhaps more effi cacious , approach	41952
@NP	the co-transplantation of OEG and MSC	42000
@NP	the co-transplantation	42000
@NP	OEG and MSC	42026
@NP	Acknowledgments	42040
@NP	We	42056
@NP	James Dutt for critical reading of the manuscript	42065
@NP	James Dutt	42065
@NP	critical reading of the manuscript	42080
@NP	critical reading	42080
@NP	the manuscript	42100
@NP	This work	42116
@NP	the following grants	42143
@NP	AVOZ50390703 , IAA500390902 , GACR309/06/1246 , LC554 , 1M0538 and 1A8697-5	42165
@NP	The EU FP6 project ENINET -LRB- LSHM-CT-2005 -- 019063 .	42238
@NP	The EU FP6 project ENINET -LRB- LSHM-CT-2005	42238
@NP	The EU FP6 project	42238
@NP	ENINET -LRB- LSHM-CT-2005	42257
@NP	019063	42278
@NP	Declaration of interest	42286
@NP	Declaration	42286
@NP	interest	42301
@NP	The authors	42311
@NP	no confl icts of interest	42330
@NP	no confl icts	42330
@NP	interest	42347
@NP	The authors	42357
@NP	the content and writing of the paper	42395
@NP	the content and writing	42395
@NP	the paper	42422
@NP	References 1 .	42434
@VP	aims	513
@VP	producing trophic factors and cytokines	721
@VP	was studied to clarify their additive and / or synergistic effects on SCI	823
@VP	studied to clarify their additive and / or synergistic effects on SCI	827
@VP	to clarify their additive and / or synergistic effects on SCI	835
@VP	clarify their additive and / or synergistic effects on SCI	838
@VP	was used to produce SCI in rats	943
@VP	used to produce SCI in rats	947
@VP	to produce SCI in rats	952
@VP	produce SCI in rats	955
@VP	were implanted by intraspinal injection 1 week after SCI	1039
@VP	implanted by intraspinal injection 1 week after SCI	1044
@VP	was assessed using behavioral , electrophysiologic and histologic methods	1127
@VP	assessed using behavioral , electrophysiologic and histologic methods	1131
@VP	using behavioral , electrophysiologic and histologic methods	1140
@VP	examined with Basso , Beattie and Bresnahan -LRB- BBB -RRB- and Plantar tests	1232
@VP	found in all three groups of transplanted rats with different time -- courses	1316
@VP	was no signifi cant difference among the groups at the end of the experiment	1402
@VP	decreased in amplitude from 7 mV to 10 μV	1514
@VP	were signifi cantly spared by transplantation after SCI	1743
@VP	spared by transplantation after SCI	1763
@VP	was achieved with transplantation of OEG and/or MSC	1836
@VP	achieved with transplantation of OEG and/or MSC	1840
@VP	did not show synergistic effects	1931
@VP	show synergistic effects	1939
@VP	might prevent their concerted action	1999
@VP	prevent their concerted action	2005
@VP	might be benefi cial for SCI therapy	2145
@VP	be benefi cial for SCI therapy	2151
@VP	restoring locomotor function after spinal cord injury -LRB- SCI -RRB-	2237
@VP	have been investigated extensively as promising candidates for cell therapy	2372
@VP	been investigated extensively as promising candidates for cell therapy	2377
@VP	investigated extensively as promising candidates for cell therapy	2382
@VP	regulating astrocytes and promoting angiogenesis and myelination -LRB- 1,2 -RRB-	2523
@VP	regulating astrocytes	2523
@VP	promoting angiogenesis and myelination -LRB- 1,2 -RRB-	2549
@VP	has inhibitory effects on growing axons following SCI -LRB- 3,4 -RRB-	2669
@VP	create a permissive environment	2748
@VP	spared	2784
@VP	are genetically closer to Schwann cells than astrocytes	3061
@VP	are more related to OEG than to oligodendrocytes -LRB- 8 -RRB-	3133
@VP	established following SCI	3364
@VP	regulated laminin-1 production	3500
@VP	to interact , resulting in the re-entry of regenerating axons into the CNS	3572
@VP	interact , resulting in the re-entry of regenerating axons into the CNS	3575
@VP	resulting in the re-entry of regenerating axons into the CNS	3585
@VP	regenerating axons into the CNS	3614
@VP	can be attracted to the lesion site , where they can secrete cytokines	3739
@VP	be attracted to the lesion site , where they can secrete cytokines	3743
@VP	attracted to the lesion site , where they can secrete cytokines	3746
@VP	can secrete cytokines	3787
@VP	secrete cytokines	3791
@VP	can exert an inhibitory infl uence on scarring and apoptosis	3849
@VP	exert an inhibitory infl uence on scarring and apoptosis	3853
@VP	facilitate angiogenesis and neural regeneration -LRB- 11 -RRB-	3916
@VP	Mobilized from the bone marrow -LRB- BM -RRB- , and sorted	3970
@VP	Mobilized from the bone marrow -LRB- BM -RRB-	3970
@VP	sorted	4011
@VP	expanded in culture	4021
@VP	can be delivered to the damaged site by direct or systemic application	4046
@VP	be delivered to the damaged site by direct or systemic application	4050
@VP	delivered to the damaged site by direct or systemic application	4053
@VP	are attractive characteristics from a therapeutic point of view	4742
@VP	may be benefi cial for SCI treatment through a combinatory approach	4845
@VP	be benefi cial for SCI treatment through a combinatory approach	4849
@VP	can improve functional outcome by producing trophic factors and cytokines	5087
@VP	improve functional outcome by producing trophic factors and cytokines	5091
@VP	producing trophic factors and cytokines	5121
@VP	can be used in autologous transplantation protocols	5194
@VP	be used in autologous transplantation protocols	5198
@VP	used in autologous transplantation protocols	5201
@VP	would be necessary	5293
@VP	be necessary	5299
@VP	was studied	5489
@VP	studied	5493
@VP	weighing 270	5534
@VP	were used in our experiments	5553
@VP	used in our experiments	5558
@VP	were divided into four groups	5604
@VP	divided into four groups	5609
@VP	received both OEG and MSC -LRB- n = 21 -RRB-	5652
@VP	was injected with saline as a control -LRB- n = 23 -RRB-	5805
@VP	injected with saline as a control -LRB- n = 23 -RRB-	5809
@VP	was used to create an SCI	6164
@VP	used to create an SCI	6168
@VP	to create an SCI	6173
@VP	create an SCI	6176
@VP	was performed	6241
@VP	performed	6245
@VP	was inserted below T8	6284
@VP	inserted below T8	6288
@VP	was infl ated with 15 μL saline for 5 min at T8 -LRB- 19,21 -RRB-	6323
@VP	ated with 15 μL saline for 5 min at T8 -LRB- 19,21 -RRB-	6332
@VP	was maintained at 37 °C with a heating pad	6446
@VP	maintained at 37 °C with a heating pad	6450
@VP	prevent edema development as a result of low levels of anesthesia -LRB- 22 -RRB-	6564
@VP	had recovered suffi ciently to perform these functions on their own	6730
@VP	recovered suffi ciently to perform these functions on their own	6734
@VP	to perform these functions on their own	6758
@VP	perform these functions on their own	6761
@VP	to prevent post-operative infections	6860
@VP	prevent post-operative infections	6863
@VP	were obtained from 4-week-old Wistar rats	6938
@VP	obtained from 4-week-old Wistar rats	6943
@VP	was scraped from both sides of the nasal septum	7002
@VP	scraped from both sides of the nasal septum	7006
@VP	separated mechanically from the epithelium and dissociated with collagenase type	7133
@VP	separated mechanically from the epithelium	7133
@VP	dissociated with collagenase type	7180
@VP	ed Eagle medium -LRB- DMEM -RRB- / F12 with 10 % fetal bovine serum	7295
@VP	to eliminate rapidly dividing cells , such as fi broblasts ,	7430
@VP	eliminate rapidly dividing cells , such as fi broblasts ,	7433
@VP	dividing cells , such as fi broblasts ,	7451
@VP	To assess the purity of OEG cultures , cultured cells on glass slides	7557
@VP	assess the purity of OEG cultures , cultured cells on glass slides	7560
@VP	cultured cells on glass slides	7595
@VP	were fi xed in 4 % paraformaldehyde , permeabilized in 0.1 % Triton X-100	7626
@VP	xed in 4 % paraformaldehyde , permeabilized in 0.1 % Triton X-100	7634
@VP	blocked in serum , and incubated with primary antibodies	7698
@VP	blocked in serum	7698
@VP	incubated with primary antibodies	7720
@VP	were used to distinguish the two primary antibodies	8076
@VP	used to distinguish the two primary antibodies	8081
@VP	to distinguish the two primary antibodies	8086
@VP	distinguish the two primary antibodies	8089
@VP	Labeled cells	8129
@VP	were examined in a fl	8143
@VP	examined in a fl	8148
@VP	cultured cells	8241
@VP	were p75/S100-positive	8256
@VP	ushing with DMEM	8370
@VP	dissociated mechanically	8402
@VP	were isolated through their adherence to plastic	8555
@VP	isolated through their adherence to plastic	8560
@VP	were removed by replacing the medium -LRB- 19,25 -RRB-	8686
@VP	removed by replacing the medium -LRB- 19,25 -RRB-	8691
@VP	replacing the medium -LRB- 19,25 -RRB-	8702
@VP	were used for transplantation after 6 -- 10 passages	8736
@VP	used for transplantation after 6 -- 10 passages	8741
@VP	were transplanted 1 week after SCI	8815
@VP	were labeled with the fl uorescent dye 10 μM carboxy-fl uorescein	8884
@VP	labeled with the fl uorescent dye 10 μM carboxy-fl uorescein	8889
@VP	dye 10 μM carboxy-fl uorescein	8919
@VP	to enable subsequent identifi cation of transplanted cells	9146
@VP	enable subsequent identifi cation of transplanted cells	9149
@VP	Labeling	9206
@VP	was performed according to the manufacturer 's instructions	9215
@VP	performed according to the manufacturer 's instructions	9219
@VP	was exposed at T8	9634
@VP	exposed at T8	9638
@VP	to prevent leakage of the cell suspension	10210
@VP	prevent leakage of the cell suspension	10213
@VP	To enable more easily distinguishable and stable tracking of transplanted cells	10629
@VP	enable more easily distinguishable and stable tracking of transplanted cells	10632
@VP	isolated from GFP + rats	10775
@VP	were used in 2-month survival experiments	10799
@VP	used in 2-month survival experiments	10804
@VP	subsequently sent to our institute	11074
@VP	bred in our animal facility	11113
@VP	described by Basso et al. -LRB- 29 -RRB-	11391
@VP	were evaluated using a 0 -- 21-point scale	11524
@VP	evaluated using a 0 -- 21-point scale	11529
@VP	using a 0 -- 21-point scale	11539
@VP	placed in a clear plastic chamber	11772
@VP	acclimated for 10 min	11810
@VP	becoming quiescent	11838
@VP	received a heat stimulus through a glass plate	11870
@VP	were measured three times for each hindpaw at 5-min intervals	11943
@VP	measured three times for each hindpaw at 5-min intervals	11948
@VP	was used for statistical evaluation	12034
@VP	used for statistical evaluation	12038
@VP	were anesthetized with ketamine -LRB- 100 mg/kg -RRB-	12100
@VP	were fi ltered -LRB- 1 -- 5000 Hz -RRB-	12313
@VP	count the number of transplanted GFP cells	12756
@VP	examine the possible neural differentiation of the transplanted cells	12803
@VP	were made after 4 % paraformaldehyde fi xation	12942
@VP	made after 4 % paraformaldehyde fi xation	12947
@VP	was chosen for imaging using a fl uorescent microscope	13009
@VP	chosen for imaging using a fl uorescent microscope	13013
@VP	using a fl uorescent microscope	13032
@VP	were counted in each section	13085
@VP	counted in each section	13090
@VP	estimated according to the volume of the section in which the cells were found	13149
@VP	were found	13217
@VP	found	13222
@VP	surviving transplanted cells	13247
@VP	blocked with 1 % bovine serum albumin	13456
@VP	followed by incubation	13634
@VP	To assess spared descending axon tracts after SCI	13713
@VP	assess spared descending axon tracts after SCI	13716
@VP	spared descending axon tracts after SCI	13723
@VP	descending axon tracts after SCI	13730
@VP	was anterogradely labeled	13844
@VP	anterogradely labeled	13848
@VP	biotinylated dextran amine -LRB- BDA ; 10 000 MW ; Molecular Probes -RRB-	13933
@VP	opened	14225
@VP	followed by 4 % paraformaldehyde solution in phosphate buffer	14291
@VP	was removed and left in paraformaldehyde solution overnight	14371
@VP	removed and left in paraformaldehyde solution overnight	14375
@VP	xed in the same solution for at least 1 week	14516
@VP	was dissected	14636
@VP	dissected	14640
@VP	were cut	14692
@VP	cut	14697
@VP	To visualize the BDA-injected corticospinal tract axons	14702
@VP	visualize the BDA-injected corticospinal tract axons	14705
@VP	were stained with hematoxylin-eosin	14947
@VP	stained with hematoxylin-eosin	14952
@VP	results in the formation of cavities within the spinal cord tissue	15003
@VP	induces degeneration of the spinal cord	15074
@VP	was analyzed at the end of the experiment	15162
@VP	analyzed at the end of the experiment	15166
@VP	was dissected between 1-cm cranial and 1-cm caudal to the injury epicenter	15286
@VP	dissected between 1-cm cranial and 1-cm caudal to the injury epicenter	15290
@VP	made after paraffi n embedding	15402
@VP	embedding	15423
@VP	to distinguish the white and gray matter	15484
@VP	distinguish the white and gray matter	15487
@VP	were selected at 1-mm intervals along the cranio-caudal axis	15568
@VP	selected at 1-mm intervals along the cranio-caudal axis	15573
@VP	taken with an Axioskop 2 plus microscope -LRB- Zeiss -RRB-	15671
@VP	are expressed as mean ± SEM	15854
@VP	expressed as mean ± SEM	15858
@VP	was used to evaluate differences between groups	15955
@VP	used to evaluate differences between groups	15959
@VP	to evaluate differences between groups	15964
@VP	evaluate differences between groups	15967
@VP	were applied for MEP	16024
@VP	applied for MEP	16029
@VP	was considered statistically signifi cant	16063
@VP	considered statistically signifi cant	16067
@VP	assessed 1 week after SCI , i.e. before transplantation -LRB- Tx -RRB-	16188
@VP	evaluated weekly thereafter	16253
@VP	Transplanted	16282
@VP	did not reveal any signifi cant differences between one other	16300
@VP	reveal any signifi cant differences between one other	16308
@VP	to withdraw the hindlimb in response to a heat stimulus	16526
@VP	withdraw the hindlimb in response to a heat stimulus	16529
@VP	was measured by the Plantar test	16582
@VP	measured by the Plantar test	16586
@VP	Transplanted	16616
@VP	improved their response to the thermal stimulus	16634
@VP	marks the day of transplantation	16889
@VP	recorded in transplanted and control rats 6 weeks after SCI -LRB- A -RRB-	16953
@VP	obtained from individual animals	17075
@VP	are shown as solid lines	17235
@VP	shown as solid lines	17239
@VP	see the Methods	17331
@VP	obtained from GFP transgenic rats	17427
@VP	showed brilliant green color in the spinal cord 9 weeks after SCI	17461
@VP	did not have such long and thin processes as OEG	17532
@VP	have such long and thin processes as OEG	17540
@VP	Transplanted OEG	17582
@VP	appeared to form a conduit by attaching to each other	17599
@VP	to form a conduit by attaching to each other	17608
@VP	form a conduit by attaching to each other	17611
@VP	attaching to each other	17629
@VP	Cultured OEG expressing p75 -LRB- D -RRB-	17654
@VP	expressing p75 -LRB- D -RRB-	17667
@VP	extended their long processes and contacted each other	17686
@VP	extended their long processes	17686
@VP	contacted each other	17720
@VP	was characterized by copious vacuoles	17777
@VP	characterized by copious vacuoles	17781
@VP	were not clearly observable in the control animals -LRB- E -RRB-	17842
@VP	plotted at 1-mm increments from the injury epicenter , which is shown as 0	18068
@VP	is shown as 0	18128
@VP	shown as 0	18131
@VP	indicate the distance from the injury epicenter in millimeters	18151
@VP	are indicated according to the type of transplanted cell	18232
@VP	indicated according to the type of transplanted cell	18236
@VP	calculated from area measurements	18354
@VP	summed from 21-mm long segments of the lesioned spinal cord	18392
@VP	were implanted	18845
@VP	implanted	18850
@VP	was no signifi cant difference in the white matter volume -LRB- C -RRB-	18867
@VP	preserved around the injection sites -LRB- D -RRB- -LRB- ∗ ∗ P < 0.01 -RRB-	18969
@VP	test	19048
@VP	was examined weekly after SCI using an open-fi eld BBB test	19074
@VP	examined weekly after SCI using an open-fi eld BBB test	19078
@VP	using an open-fi eld BBB test	19104
@VP	started to regain their ability to move during the fi rst post-surgical week	19276
@VP	to regain their ability to move during the fi rst post-surgical week	19284
@VP	regain their ability to move during the fi rst post-surgical week	19287
@VP	to move during the fi rst post-surgical week	19308
@VP	move during the fi rst post-surgical week	19311
@VP	placed their paws on the ground	19376
@VP	never supported their body weight on their hind legs	19548
@VP	already showed a tendency to improve their BBB scores	19673
@VP	to improve their BBB scores	19699
@VP	improve their BBB scores	19702
@VP	was observed in animals transplanted with OEG	19780
@VP	observed in animals transplanted with OEG	19784
@VP	transplanted with OEG	19804
@VP	was 9.30 ± 0.46	19968
@VP	received six injections	20038
@VP	improve ment 6 weeks after SCI , with a fi nal BBB	20099
@VP	recovered their gait	20348
@VP	to support their body weight	20402
@VP	support their body weight	20405
@VP	to perform paw stepping , and two animals from the OEG	20435
@VP	perform paw stepping , and two animals from the OEG	20438
@VP	stepping	20450
@VP	showed co-ordination of the forelimbs and hindlimbs	20518
@VP	improve ment at the end of the experiment -LRB- P < 0.05 -RRB-	20708
@VP	was measured once a week	20848
@VP	measured once a week	20852
@VP	determined from three repeated measurements at 5-min intervals	20982
@VP	slightly decreased during the second week following lesion induction	21209
@VP	did not continue to improve further	21297
@VP	continue to improve further	21305
@VP	to improve further	21314
@VP	improve further	21317
@VP	shortened their withdrawal latency during each subsequent week	21362
@VP	started to appear in the transplanted rats during the sixth post-surgical week	21484
@VP	to appear in the transplanted rats during the sixth post-surgical week	21492
@VP	appear in the transplanted rats during the sixth post-surgical week	21495
@VP	was never observed after OEG and/or MSC transplantation	21847
@VP	observed after OEG and/or MSC transplantation	21857
@VP	were recorded during and after the induction of the balloon compression lesion	21938
@VP	recorded during and after the induction of the balloon compression lesion	21943
@VP	was 7.19 ± 0.41 mV on average in intact rats	22044
@VP	was infl ated with saline	22107
@VP	ated with saline	22116
@VP	was recorded	22155
@VP	recorded	22159
@VP	were obtained again 1 min after balloon infl ation	22173
@VP	obtained again 1 min after balloon infl ation	22178
@VP	did not increase further their amplitude immediately after the surgery	22361
@VP	increase further their amplitude immediately after the surgery	22369
@VP	were elicited weekly from 2 weeks to 6 weeks after SCI	22437
@VP	elicited weekly from 2 weeks to 6 weeks after SCI	22442
@VP	recorded in all animals	22621
@VP	displayed according to the type of transplanted cells	22646
@VP	was used to analyze the signifi cance of the increase in MEP amplitude over time	22750
@VP	used to analyze the signifi cance of the increase in MEP amplitude over time	22754
@VP	to analyze the signifi cance of the increase in MEP amplitude over time	22759
@VP	analyze the signifi cance of the increase in MEP amplitude over time	22762
@VP	did not show any improvement in amplitude	22984
@VP	show any improvement in amplitude	22992
@VP	stabilized between 15 and 40 μV 6 weeks after lesioning	23030
@VP	lesioning	23076
@VP	showed more improvement than the control group	23124
@VP	were 5.55 ± 1.37 ms and 4.81 ± 0.67 ms in the intact animals , respectively	23692
@VP	was extended by 1 ms after SCI	23788
@VP	extended by 1 ms after SCI	23792
@VP	quickly decreased in the OEG/MSC - and MSCtransplanted groups	23849
@VP	gradually shortened week by week in the OEG-transplanted and control groups	23915
@VP	not shown	24147
@VP	was not signifi cantly different from normal values throughout the experiment	24171
@VP	revealed a tendency towards decreased latency in the transplanted groups	24277
@VP	was no such tendency observed in the control group -LRB- Figure 2C -RRB-	24515
@VP	observed in the control group -LRB- Figure 2C -RRB-	24536
@VP	To monitor cell survival in SCI	24604
@VP	monitor cell survival in SCI	24607
@VP	examined longitudinal cryosections of the ballooncompressed spinal cord	24640
@VP	expressed by CFDA-SE-labeled OEG	24737
@VP	were visible for only 4 or 5 weeks after SCI -LRB- Figure 3A -RRB-	24912
@VP	labeled	24984
@VP	were not seen	24996
@VP	seen	25005
@VP	dye was not adequate for longer observation	25058
@VP	was not adequate for longer observation	25062
@VP	to enable more reliable tracking of the cells in vivo	25114
@VP	enable more reliable tracking of the cells in vivo	25117
@VP	obtained from GFP transgenic rats	25181
@VP	were used for long-term tracking	25215
@VP	used for long-term tracking	25220
@VP	were injected and checked every week in the same way	25284
@VP	injected and checked every week in the same way	25289
@VP	injected	25289
@VP	checked every week in the same way	25302
@VP	Surviving MSC -LRB- Figure 3B -RRB- and OEG -LRB- Figure 3C -RRB- from GFP rats	25338
@VP	were easily recognized by their vivid green color in the spinal cord for 8 weeks	25398
@VP	recognized by their vivid green color in the spinal cord for 8 weeks	25410
@VP	were almost exclusively found around the injection sites	25581
@VP	almost exclusively found around the injection sites	25586
@VP	were slightly diffused by the injection pressure	25641
@VP	slightly diffused by the injection pressure	25646
@VP	extended their long processes and remained in close contact with one another	25762
@VP	extended their long processes	25762
@VP	remained in close contact with one another	25796
@VP	was also observed in vitro	26004
@VP	observed in vitro	26013
@VP	to grasp each other by tangling their long processes -LRB- Figure 3D -RRB-	26046
@VP	grasp each other by tangling their long processes -LRB- Figure 3D -RRB-	26049
@VP	tangling their long processes -LRB- Figure 3D -RRB-	26069
@VP	was counted	26173
@VP	counted	26177
@VP	were great differences between individual animals even in the same group	26192
@VP	surviving MSC and OEG was 0.41	26284
@VP	was 0.41	26306
@VP	were observed in the co-transplanted group	26379
@VP	observed in the co-transplanted group	26384
@VP	was identifi	26711
@VP	ed as the thinnest part of the thoracic spinal cord	26724
@VP	plotted at 1-mm increments from the injury epicenter -LRB- Figure 4A , B -RRB-	26842
@VP	reached statistical signifi cance	27113
@VP	was calculated from area measurements and summed from 21-mm long segments	27205
@VP	calculated from area measurements and summed from 21-mm long segments	27209
@VP	calculated from area measurements	27209
@VP	summed from 21-mm long segments	27247
@VP	calculated from 21-mm long segments	27588
@VP	was equally preserved in the cranial and caudal segments	28214
@VP	preserved in the cranial and caudal segments	28226
@VP	were transplanted	28531
@VP	transplanted	28536
@VP	was prominently spared around the injection sites -LRB- Figure 5C , D -RRB-	28578
@VP	spared around the injection sites -LRB- Figure 5C , D -RRB-	28594
@VP	tracing	28788
@VP	was spared	28852
@VP	spared	28856
@VP	were more visible in the spared white matter -LRB- Figure 3F -RRB-	28888
@VP	seen around the injury epicenter in the control rats -LRB- Figure 3E -RRB-	28966
@VP	characterized by infl ammation	29373
@VP	is maximally activated	29630
@VP	maximally activated	29633
@VP	sprouting by removing cell debris	29706
@VP	removing cell debris	29719
@VP	is blocked immediately after SCI	29866
@VP	blocked immediately after SCI	29869
@VP	is decreased	29921
@VP	decreased	29924
@VP	activating microglia and macrophages -LRB- 34 -RRB-	30025
@VP	released from proliferating microglia -LRB- 35 -RRB-	30243
@VP	were transplanted at 7 days after SCI in our study	30304
@VP	transplanted at 7 days after SCI in our study	30309
@VP	show that hindlimb locomotion improved in OEG - and MSC-transplanted rats	30409
@VP	improved in OEG - and MSC-transplanted rats	30439
@VP	did not yield further additive and synergistic functional improvements	30517
@VP	yield further additive and synergistic functional improvements	30525
@VP	to have a propensity to migrate towards an injury site -LRB- 36 -- 38 -RRB-	30608
@VP	have a propensity to migrate towards an injury site -LRB- 36 -- 38 -RRB-	30611
@VP	to migrate towards an injury site -LRB- 36 -- 38 -RRB-	30629
@VP	migrate towards an injury site -LRB- 36 -- 38 -RRB-	30632
@VP	were predominantly observed around the injection sites	30704
@VP	observed around the injection sites	30723
@VP	were injected inside the lesions	30792
@VP	injected inside the lesions	30797
@VP	would not need to migrate any considerable distance	30834
@VP	need to migrate any considerable distance	30844
@VP	to migrate any considerable distance	30849
@VP	migrate any considerable distance	30852
@VP	be one of the features of OEG obtained from the lamina propria -LRB- 39 -RRB-	30933
@VP	obtained from the lamina propria -LRB- 39 -RRB-	30963
@VP	enhanced the adhesion of OEG via activation of Rho-A and limited their migration	31087
@VP	enhanced the adhesion of OEG via activation of Rho-A	31087
@VP	limited their migration	31144
@VP	induced the formation of MSC focal adhesions -LRB- 43,44 -RRB-	31224
@VP	were implanted by separate injections in our experiments	31363
@VP	implanted by separate injections in our experiments	31368
@VP	facilitate cell migration	31549
@VP	promote axonal growth	31586
@VP	prevent apoptosis in the injured spinal cord -LRB- 40,45 -RRB-	31612
@VP	To treat SCI	31666
@VP	treat SCI	31669
@VP	to establish new neural circuits to bypass the injured sites	31856
@VP	establish new neural circuits to bypass the injured sites	31859
@VP	to bypass the injured sites	31889
@VP	bypass the injured sites	31892
@VP	sprout and send collaterals into the gray matter -LRB- 46 -- 48 -RRB-	31947
@VP	is very much dependent on this newly established route	32128
@VP	showed very variable amplitudes in each group and even in the same animal	32213
@VP	were not exactly the same for every measurement	32333
@VP	do not affect the animal 's locomotion and behavior	32554
@VP	affect the animal 's locomotion and behavior	32561
@VP	had variable amplitudes and remained within microvolt-levels	32626
@VP	had variable amplitudes	32626
@VP	remained within microvolt-levels	32654
@VP	analyzed during a 1-month observation period	32729
@VP	was statistically signifi cant in the transplanted groups	32775
@VP	did not show any improvement in amplitude	32852
@VP	show any improvement in amplitude	32860
@VP	improved their amplitude week by week	32923
@VP	showed the greatest improvement among the transplanted groups	33004
@VP	were partially saved in the incompletely damaged spinal cord	33233
@VP	saved in the incompletely damaged spinal cord	33248
@VP	shortened	33323
@VP	improved	33334
@VP	was observed only in the transplanted groups	33352
@VP	observed only in the transplanted groups	33356
@VP	spared and recovered circuits for locomotor activity	33427
@VP	were not enough to elicit high MEP amplitudes	33480
@VP	to elicit high MEP amplitudes	33496
@VP	elicit high MEP amplitudes	33499
@VP	stepping	33598
@VP	corresponds with histologic fi ndings of residual axons in the spinal cord	33681
@VP	survived in the spinal cord after SCI and sustained neurologic function in rats	33805
@VP	results in demyelination -LRB- 55,56 -RRB-	34004
@VP	was signifi cant only in the co-transplanted group	34238
@VP	might be partly involved in this functional improvement	34316
@VP	be partly involved in this functional improvement	34322
@VP	partly involved in this functional improvement	34325
@VP	play an important role in more sophisticated locomotion -LRB- 59 -RRB-	34397
@VP	requires parallel paw position during locomotion	34532
@VP	was placed on , and lifted from , the fl oor	34680
@VP	placed on , and lifted from , the fl oor	34684
@VP	placed on	34684
@VP	lifted from	34699
@VP	were implanted intravenously -LRB- 19 -RRB-	34842
@VP	implanted intravenously -LRB- 19 -RRB-	34847
@VP	may cause additional damage to the dorsal columns	34907
@VP	cause additional damage to the dorsal columns	34911
@VP	may not be as reliable in the present study as in our previous MSC study	34992
@VP	be as reliable in the present study as in our previous MSC study	35000
@VP	showed similar results	35118
@VP	are different in restoring the damaged spinal cord	35169
@VP	restoring the damaged spinal cord	35186
@VP	improves locomotor activity and signifi cantly	35290
@VP	increases spared white matter in the lesion area -LRB- 19 -RRB-	35337
@VP	spared white matter in the lesion area -LRB- 19 -RRB-	35347
@VP	was observed	35427
@VP	observed	35431
@VP	are known to have immunomodulatory effects -LRB- 60 -RRB-	35445
@VP	known to have immunomodulatory effects -LRB- 60 -RRB-	35449
@VP	to have immunomodulatory effects -LRB- 60 -RRB-	35455
@VP	have immunomodulatory effects -LRB- 60 -RRB-	35458
@VP	may infl uence the levels of pro- and anti-infl ammatory cytokines	35530
@VP	infl uence the levels of pro- and anti-infl ammatory cytokines	35534
@VP	might result in a trophic effect on functional recovery	35607
@VP	result in a trophic effect on functional recovery	35613
@VP	is not fully developed at 7 days after SCI	35681
@VP	developed at 7 days after SCI	35694
@VP	may act as a neuroprotective agent	35736
@VP	act as a neuroprotective agent	35740
@VP	observed in the Plantar test	35793
@VP	showed the poor survival of OEG and MSC implanted into the lesioned area	35938
@VP	implanted into the lesioned area	35978
@VP	spared the gray matter in our study	36051
@VP	is not a habitable environment for transplanted cells -LRB- 31 -RRB-	36113
@VP	avoid additional damage to the spinal cord	36268
@VP	enable more effi cient cell delivery to the spinal cord -LRB- 61,62 -RRB-	36315
@VP	transported to the subarachnoid space in the spinal cord through the CSF	36554
@VP	promoted behavioral recovery after SCI	36631
@VP	using an immunosuppressant -LRB- 63 -RRB-	36734
@VP	was 0 -- 0.013 mm2 in the control animals	37184
@VP	remained spared in the treated animals	37256
@VP	spared in the treated animals	37265
@VP	sparing	37691
@VP	sparing resulting from OEG transplantation	37768
@VP	resulting from OEG transplantation	37776
@VP	might lead to the faster recovery of simple locomotor function	37915
@VP	lead to the faster recovery of simple locomotor function	37921
@VP	were mainly implanted	38098
@VP	mainly implanted	38103
@VP	was found in the volume of the gray matter	38275
@VP	found in the volume of the gray matter	38279
@VP	had the ability to spare the white and gray matter in the injured spinal cord	38331
@VP	to spare the white and gray matter in the injured spinal cord	38347
@VP	spare the white and gray matter in the injured spinal cord	38350
@VP	were directly injected	38525
@VP	directly injected	38530
@VP	is more susceptible to metabolic damage than white matter	38565
@VP	includes ischemic damage to the spinal cord	38644
@VP	leads to metabolic failure in the gray matter	38692
@VP	showed that the transplants spared the gray matter from such damage	38742
@VP	spared the gray matter from such damage	38770
@VP	remained	38870
@VP	was poorly spared	38900
@VP	poorly spared	38904
@VP	appear to secure more descending and ascending axons by sparing the white matter	38931
@VP	to secure more descending and ascending axons by sparing the white matter	38938
@VP	secure more descending and ascending axons by sparing the white matter	38941
@VP	descending and ascending axons by sparing the white matter	38953
@VP	sparing the white matter	38987
@VP	to reconstruct lost connections by sending collaterals from the spared axons	39060
@VP	reconstruct lost connections by sending collaterals from the spared axons	39063
@VP	sending collaterals from the spared axons	39095
@VP	was also spared by the transplants	39163
@VP	spared by the transplants	39172
@VP	can re-establish or maintain neural connections with the PNS and CNS	39232
@VP	re-establish or maintain neural connections with the PNS and CNS	39236
@VP	were not implanted	39320
@VP	implanted	39329
@VP	showed the ability to support their body weight on their hind legs	39358
@VP	to support their body weight on their hind legs	39377
@VP	support their body weight on their hind legs	39380
@VP	must be considered from the viewpoint of synaptic reconstruction	39583
@VP	be considered from the viewpoint of synaptic reconstruction	39588
@VP	considered from the viewpoint of synaptic reconstruction	39591
@VP	induced by transplantation	39687
@VP	increases the feasibility of this reconstruction	39714
@VP	to differentiate into mesodermal and non-mesodermal lineages -LRB- 64 -RRB-	39799
@VP	differentiate into mesodermal and non-mesodermal lineages -LRB- 64 -RRB-	39802
@VP	are prone to differentiate into the mesodermal lineage	39871
@VP	to differentiate into the mesodermal lineage	39881
@VP	differentiate into the mesodermal lineage	39884
@VP	to differentiate into neuronal cells	39943
@VP	differentiate into neuronal cells	39946
@VP	is limited and remains controversial -LRB- 65,66 -RRB-	39980
@VP	is limited	39980
@VP	limited	39983
@VP	remains controversial -LRB- 65,66 -RRB-	39995
@VP	were not found 2 months after transplantation	40106
@VP	found 2 months after transplantation	40115
@VP	might help to bridge the damaged neural circuits	40255
@VP	help to bridge the damaged neural circuits	40261
@VP	to bridge the damaged neural circuits	40266
@VP	bridge the damaged neural circuits	40269
@VP	could foster locomotor function by sparing the spinal cord	40538
@VP	foster locomotor function by sparing the spinal cord	40544
@VP	sparing the spinal cord	40573
@VP	provide no added benefi t to SCI therapy	40628
@VP	trophic factors might need to be considered for further functional improvement	40839
@VP	might need to be considered for further functional improvement	40855
@VP	need to be considered for further functional improvement	40861
@VP	to be considered for further functional improvement	40866
@VP	be considered for further functional improvement	40869
@VP	considered for further functional improvement	40872
@VP	spared the white matter after SCI , but not the gray matter -LRB- 19 -RRB-	40973
@VP	used in the current study	41189
@VP	found signifi cantly more gray matter sparing following intraspinal injection	41219
@VP	matter sparing following intraspinal injection	41250
@VP	sparing following intraspinal injection	41257
@VP	is considered 100 %	41342
@VP	considered 100 %	41345
@VP	received OEG transplants	41724
@VP	Taken together	41750
@VP	accompanied by intravenous injection of MSC	41899
@VP	thank James Dutt for critical reading of the manuscript	42059
@VP	report no confl icts of interest	42323
@VP	are responsible for the content and writing of the paper	42375
